多発性嚢胞腎の全て

出版社： インターメディカ
著者：
発行日： 2006-06-14
分野： 臨床医学：内科  >  腎臓
ISBN： 4899961685
電子書籍版： 2006-06-14 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,950 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,455 円(税込)

購入する

商品紹介

本書は、2001年の「多発性嚢胞腎」（小出輝・東原英二編、南山堂）の跡を継ぐもので、第49回日本腎臓学会学術大会（2006年6月東京）の記念として出版されました。

目次

  • 多発性嚢胞腎の全て

    ―目次―

    1．多発性嚢胞腎の基礎
    　疫学
    　常染色体優性多発性嚢胞腎遺伝子
    　PKD蛋白（Polycystin)
    　嚢胞形成の機序
    　常染色体劣性多発性嚢胞腎

    2．多発性嚢胞腎の臨床
    　常染色体優性多発性嚢胞腎
    　常染色体劣性多発性嚢胞腎

    3．多発性嚢胞腎の治療
    　1．細胞（in vivo）レベルの実験と動物（in vivo）実験の結果
    　2．臨床試験結果
    　3．透析療法
    　4．腎移植

    4．周辺の嚢胞性腎疾患
    　1．ネフロン癆
    　2．髄質嚢胞腎
    　3．OFD 1型（oral-facial-digital syndrome）
    　4．髄質嚢胞性疾患
    　5．糸球体嚢胞性疾患
    　6．結節性硬化症
    　7．Von Hippel-Lindau病
    　8．Bardet-Biedl症候群
    　9．多嚢腎
    　10．多房性腎嚢胞（multilocular cyst）
    　11．髄質海綿腎（medullary sponge kidney）
    　12．単純性腎嚢胞
    　13．腎洞性嚢胞と傍腎盂嚢胞、腎盂周囲嚢胞
    　14．後天性嚢胞性腎疾患（多嚢胞化萎縮腎）
    　15．腎杯憩室（腎盂性憩室）
    　16．片側性嚢胞性腎疾患

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 多発性嚢胞腎の基礎

P.21 掲載の参考文献
1) Dalgaard OZ:Bilateral polycystic disease of the kidneys:A flollow up of two hundred and eighty-four patients and their families. Acta Med Acand Suppl 328:1-251, 1957.
 
2) Zrier M, Geberth S, Ritz E, et al:Adult polycystic kidney disease-clinical problems. Nephron 49:177-183, 1988.
 
3) Chan KW:Adult polycystic kidney disease in Hong Kong Chinese:An autopsy study. Pathology 25:229-232, 1993.
 
4) Davies F, Coles GA, Happer PS, et al:Polycystic kidney disease Re-evaluated:A population-based study. Q J Med 79:477-485, 1991.
 
5) Higashihara E, Nutahara K, Kojima M, et al:Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. Nephron 80:421-427, 1998.
PubMed
6) Iglesias CG, Torres VE, Offord KP, et al:Epidemiology of adult polycystic kidney disease, Olmsted county, Minnesota:1935-1980. Am J Kidney Dis 2:630-639, 1983.
PubMed
7) USRDS 1995 Annual Data Report. Chapter III, Incidence and Causes of treated ESRD. p25-37.
 
8) Milutinovic J, Fialkow PJ, Agodoa LY, et al:Autosomal dominant polycystic kidney disease:Symptoms and clinical findings. Q J Med 53:511-522, 1984.
PubMed
9) Churchill DN, Bear JC, Morgan J, et al:Prognosis of adult onset polycystic kidney disease re-evaluated. Kidney Int 26:290-193, 1984.
 
10) Gonzalo A, Rivera M, Quereda C, et al:Clinical features and prognosis of adult polycystic kidney disease. Am J Nephrol 10:470-474, 1990.
PubMed
11) Gabow PA, Johnson AM, Kaehny WD, et al:Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 41:1311-1319, 1992
PubMed
12) DE Almeida E, Sousa A, Pires C, et al:Prevalence of autosomal dominant polycystic kidney disease in Alentejo, Portugal. Kidney Int 59:2374, 2001.
 
P.22 掲載の参考文献
1) Dell KM, McDonald RA, Watkins SL, Avner ED:Polycystic kidney disease In Pediatric Nephrology. 5th ed, Avner ED, Harmon WE, Niaudet P (eds). p675-699, Lippincott Williams Wilkins, Philadelphia, 2004.
 
2) Zerres K, Mucher G, Becker J, et al:Prenatal diagnosis of autosomal recessive polycystic kidney disease (ARPKD):molecular genetics, clinical experience, and fetal morphology. Am J Med Genet 76:137-144, 1998.
PubMed
3) Zerres K, Mucher G, Becker J, et al:Autosomal recessive polycystic kidney disease. J Mol Med 76:303-309, 1998.
PubMed
4) Lonergan GJ, Rice RR, Suarez ES:Autosomal Recessive Polycystic Kidney Disease:Radiologic-Pathologic Correlation. Radiographics 20:837-855, 2000.
PubMed
5) Guay-Woodford LM, Desmond RA:Autosomal recessive polycystic kidney disease:the clinical experience in North America. Pediatrics 111:1072-80, 2003.
PubMed
6) Mucher G, Becker J, Knapp M, et al:Fine mapping of the autosomal recessive polycystic kidney disease locus (PKHD1) and the genes MUT, RDS, CSNK2 beta, and GSTA1 at 6p21. 1-p12. Genomics 48:40-45, 1998.
PubMed
7) Alvarez V, Malaga S, Navarro M, et al:Analysis of chromosome 6p in Spanish families with recessive polycystic kidney disease. Pediatr Nephrol 14:205-207, 2000.
PubMed
P.29 掲載の参考文献
1) Reeders ST, Breuning MH, Davis KE, et al:A highly polymorphic DNA marker linked to adult polycystic kidney disease on chromosome 16. Nature 317:542-544, 1985.
 
2) ヒトの分子遺伝学. 村松正實監修, メディカル・サイエンス・インターナショナル, 東京, 1997.
 
3) 望月俊雄:多発性嚢胞腎の基礎 分子遺伝学. 多発性嚢胞腎. 小出輝, 東原英二編, p16-48, 南山堂, 2001.
 
4) Germino GG, Somlo S, Weinstat-Saslow D, et al:Positional cloning approach to the dominant polycystic kidney disease gene, PKD1. Kidney Int 43 (suppl 39):S20-S25, 1993.
 
5) The Europian Polycystic Kidney Disease Consortium:Polycystic kidney disease 1 gene encodes a 14kb transcript and lies within a duplicated region on chromosome 16. Cell 77:881-894, 1994.
 
6) The European Chromosome 16 Tuberous Sclerosis Consortium:Identification and characterization of the Tuberous Sclerosis gene on chromosome 16. Cell 75:1305-1315, 1993.
PubMed
7) Hughes J, Ward CJ, Peral B, et al:The polycystic kidney disease 1 (PKD1) gene encodes anovel protein with multiple cell recognition domains. Nature Genet 10:151-160, 1995.
 
8) Bogdanova N, Markoff A, Gerke V, et al:Homologues to the first gene for autosomal dominant polycystic kidney disease are pseudogenes. Genomics 74:333-341, 2001.
 
9) Blaszak RT, Potaman V, Sinden RR, et al:DNA structural transitions within the PKD1 gene. Nucleic Acids Res 27:2610-2617, 1999.
PubMed
10) Patel HP, Lu L, Blaszak RT, et al:PKD1 intron 21:triplex DNA formation and effect on replication. Nucleic Acids Res 32:1460-1468, 2004.
PubMed
11) Rodova M, Islam MR, Peterson KR, et al:Remarkable sequence conservation of the last intron in the PKD1 gene. Mol Biol Evol 20:1669-1674, 2003.
PubMed
12) Lantinga-van Leeuwen IS, Leonhard WN, Dauwerse H, et al:Common regulatory elements in the polycystic kidney disease 1 and 2 promoter regions. Eur J Hum Genet 13:649-59, 2005.
PubMed
13) 清水淑子:透析患者の合併症とその対策 第5章多発性嚢胞腎のカウンセリング. p39-50, 日本透析医会, 2003.
 
14) Mizoguchi M, Tamura T, Yamaki A, et al:Mutations of the PKD1 gene among Japanese autosomal dominant polycystic kidney disease patients, including one heterozygous mutation identified in members of the same family. J Hum Genet 46:511, 2001.
PubMed
15) Peltola P, Lumiaho A, Miettinen R, et al:Genetics and phenotypic characteristics of autosomal dominant polycystic kidney disease in Finns. J Mol Med 83:638-646, 2005.
PubMed
16) Rossetti S, Chauveau D, Walker D, et al:A complete mutation screen of the ADPKD genes by DHPLC. Kidney Int 61:1588-1599, 2002.
 
17) Phakdeekitcharoen B, Watnick TJ, Germino GG:Mutation analysis of the entire replicated portion of PKD1 using genomic DNA samples. J am Soc Nephrol 12:955-963, 2001.
 
18) Thomas R, McConnell R, Whittacker J, et al:Identification of mutations in the repeated part of the autosomal dominant polycystic kidney disease type 1 gene, PKD1, by long-range PCR. Am J Hum Genet 65:39-49, 1999.
PubMed
19) Burtey S, Lossi AM, Bayle J, et al:Mutation screening of the PKD1 transcript by RT-PCR. J Med Genet 39:422-429, 2002.
 
20) Thongnoppakhun W, Limwongse C, Vareesangthip K, et al:Novel and de novo PKD1 mutations identified by multiple restriction fragment-single strand conformation polymorphism (MRF-SSCP). BMC Med Genet 5:2-17, 2004.
PubMed
21) Rossetti S, Strmecki L, Gamble V, et al:Mutation analysis of the entire PKD1 gene:genetic and diagnostic implications. Am J Hum Genet 68:46-63, 2001.
PubMed
22) Torra R, Badenas C, Peral B, et al:Recurrence of the PKD1 nonsense mutation Q4041X in Spanish, Italian, and British Families. Hum Mut IS117-120, 1998.
 
23) Rossetti S, Burton S, Strmecki L, et al:The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease. J Am Soc Nephrol 13:1230-1237, 2002.
PubMed
24) Rossetti S, Chauveau D, Kubly V, et al:Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Lancet 361:2196-201, 2003.
PubMed
25) Brook-Carter PT, Peral B, Ward CJ, et al:Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease:a contiguous gene syndrome. Nat Genet 8:328-332, 1994.
PubMed
26) Longa L, Scolari F, Brusco A, et al:A large TSC2 and PKD1 gene deletion is associated with renal and extrarenal signs of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 12:1900-1907, 1997.
PubMed
27) Torra R, Badenas C, Darnell A, et al:Facilitated diagnosis of the contiguous gene syndrome:tuberous sclerosis and polycystic kidneys by means of haplotype studies. Am J Kidney Dis 31:1038-1043, 1998.
PubMed
28) Sampson JR, Maheshwar MM, Aspinwall R, et al:Renal cystic disease in tuberous sclerosis:role of the polycystic kidney disease l gene. Am J Hum Genet 61:843-851, 1997.
 
29) Smulders YM, Eussen BH, Verhoef S, et al:Large deletion causing the TSC2-PKD1 contiguous gene syndrome without infantile polycystic disease. J Med Genet 40:E17, 2003.
 
P.34 掲載の参考文献
1) Kimberling WJ, Fain PR, Kenyon JB, et al:Linkage heterogeneity of autosomal dominant polycystic kidney disease. N Engl J Med 319:913-918, 1988.
PubMed
2) Kimberling WJ, Kumar S, Gabow PA, et al:Autosomal dominant polycystic kidney disease:localization of the second gene to chromosome 4q13-q23. Genomics 18:467-472, 1993.
PubMed
3) Peters DJM, Spruit L, Saris J, et al:Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease. Nature Genet 5:359-362, 1993.
 
4) Mochizuki T, Wu G, Hayashi T, et al:PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272:1339-1342, 1996.
PubMed
5) Hayashi T, Mochizuki T, Reynolds DM, et al:Characterization of the exon structure of the polycystic kidney disease 2 gene (PKD2) . Genomics 44:131-136, 1997.
PubMed
6) Lantinga-van Leeuwen IS, Leonhard WN, Dauwerse H, et al:Common regulatory elements in the polycystic kidney disease 1 and 2 promoter regions. Eur J Hum Genet 13:649-59, 2005.
PubMed
7) 清水淑子:多発性嚢胞腎の基礎2. 分子生物学的疫学. 小出輝, 東原英二, p9-15, 南光堂, 2001.
 
8) Koptides M, Hadjimichael C, Koupepidou P, et al:Germinal and somatic mutations in the PKD2 gene of renal cysts in autosomal polycystic kidney disease. Hum Mol Genet 8:509-513, 1999.
PubMed
9) Koptides M, Mean R, Demetriou K, et al:Genetic evidence for a trans-heterozygous model for cystogenesis in autosomal dominant polycystic kidney disease. Hum Mol Genet 9:447-452, 2000.
PubMed
10) Watnick T, He N, Wang K, et al:Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of trans-heterozygous mutations. Nat Genet 25:143, 2000.
PubMed
11) Pei Y, Paterson AD, Wang KR, et al:Bilineal disease and trans-heterozygotes in autosomal dominant polycystic kidney disease. Am J Hum Genet 68:355-363, 2001.
PubMed
12) Hateboer N, Veldhuisen B, Peters D, et al:Location of mutations within the PKD2 gene influences clinical outcome. Kidney Int 57:1444-1451, 2000.
PubMed
13) Magistroni R, He N, Wang K, et al:Genotype. renal function correlation in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol 14:1164-1174, 2003.
PubMed
P.36 掲載の参考文献
1) Daoust MC, Reynolds DM, Bichet DG, et al:Evidence for a third genetic locus for autosomal dominant polycystic kidney disease. Genomics 25:733-736, 1995.
PubMed
2) de Almeida S, de Almeida E, Peters D, et al:Autosomal dominant polycystic kidney disease:evidence for the existence of a third locus in a Portuguese family. Hum Genet 96:83-88, 1995.
 
3) Bogdanova N, Dworniczak B, Dragova D, et al:Genetic heterogeneity of polycystic kidney disease in Bulgaria. Hum Genet 95:645-650, 1995.
PubMed
4) Turco AE, Clementi M, Rossetti S, et al:An Italian family with autosomal dominant polycystic kidney disease unlinked to either the PKD1 or PKD2 gene. Am J Kidney Dis 28:759-761, 1996.
PubMed
5) Ariza M, Alvarez V, Marin R, et al:A family with a milder form of adult dominant polycystic kidney disease not linked to the PKD1 (16p) or PKD2 (4q) genes. J Med Genet 34:587-589, 1997.
 
6) Paterson AD, Pei Y:Is there a third gene for autosomal dominant polycystic kidney disease? Kidney Int 54:1759-1761, 1998.
 
7) Pei Y, Paterson AD, Wang KR, et al:Bilineal disease and trans-heterozygotes in autosomal dominant polycystic kidney disease. Am J Hum Genet 68:355-363, 2001.
PubMed
8) Torra R, Badenas C, Darnell A, et al:Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2. J Am Soc Nephrol 7:2142-2151, 1996.
PubMed
9) Hateboer N, v Dijk MA, Bogdanova N, et al:Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 353:103-107, 1999.
 
P.38 掲載の参考文献
1) Mizoguchi M, Tamura T, Yamaki A, et al:Genotypes of autosomal dominant polycystic kidney disease in Japanese. J Hum Genet 47 (1):51-4, 2002.
PubMed
2) Wright AF, Teague PW, et al:A study of genetic linkage heterogeneity in 35 adult-onset polycystic kidney disease families. Hum Genet 90:569-571, 1993.
PubMed
3) Bogdanova N, Dworniczak B, Dragova D, et al:Genetic heterogeneity of polycystic kidney disease in Bulgaria. Hum Genet 95:645-650, 1995.
PubMed
4) Iglesias DM, Martin RS, Fraga A, et al:Genetic heterogeneity of autosomal dominant polycystic kidney disease in Argentina. J Med Genet 34:827-830, 1997.
PubMed
P.39 掲載の参考文献
1) Nomura H, Turco AE, Pei Y, et al:Identification of PKDL, a novel polycystic kidney disease 2-like gene whose murine homologue is deleted in mice with kidney and retinal defects. J Biol Chem 273:25967-25973, 1998.
PubMed
2) Guo L, Schreiber TH, Weremowicz S, et al:Identification and characterization of a novel polycystin family member, polycystin-L2, in mouse and human:sequence, expression, alternative splicing, and chromosomal localization. Genomics 64:241-251, 2000.
PubMed
3) Chen XZ, Vassilev PM, Basora N, et al:Polycystin-L is a calcium-regulated cation channel permeable to calcium ions. Nature 401:383-386, 1999.
 
4) Volk T, Schwoerer AP, Thiessen S, et al:A polycystin-2-like large conductance cation channel in rat left ventricular myocytes. Cardiovasc Res 58:76-88, 2003.
PubMed
P.45 掲載の参考文献
1) Katsuyama M, Masuyama T, Komura I, et al:Characterization of a novel polycystic kidney rat model with accompanying polycystic liver. Exp Anim 49:51-55, 2000.
PubMed
2) Ward CJ, Hogan MC, Rossetti S, et al:The gene mutated in autosomal recessive polycystlc kidney disease encodes a large, receptor-like protein. Nat Genet 30:259-269, 2002.
PubMed
3) Masyuk TV, Huang BQ, Masyuk AI, et al:Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease. Am J Pathol 165:1719-1730, 2004.
PubMed
4) Lager DJ, Qian Q, Bengal RJ, et al:The pck rat:a new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int 59:126-136, 2001.
 
5) Takahashi H, Calvet JP, Dittemore-Hoover D, et al:A hereditary model of slowly progressive polycystic kidney disease in the mouse. J Am Soc Nephrogl 1:980-989, 1991.
PubMed
6) Olbrich H, Fliegauf M, Hoefele J, et al:Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis. Nat Genet 34:455-459, 2003.
 
7) Nagao S, Hibino T, Koyama Y, et al:Strain difference in expression of the adult-type polycystic kidney disease gene, pcy, in the mouse. Exp Animal 40:45-53, 1991.
 
8) Brown JH, Bihoreau MT, Hoffmann S, et al:Missense mutation in sterile alpha motif of novel protein SamCystin is associated with polycystic kidney disease in (cy/+) rat. J Am Soc Nephrol 16:3517-3526, 2005.
 
9) Nagao S, Kusaka M, Nishii K, et al:Androgen receptor pathway in rats with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 16:2052-2062, 2005.
PubMed
10) Nagao S, Yamaguchi T, Kusaka M, et al:Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease. Kidney Int 63:427-437, 2003.
PubMed
11) Hou X, Mrug M, Yoder BK, et al:a novel cilia-associated protein, is disrupted in the cpk mouse model of polycystic kidney disease. J Clin Invest 109:533-540, 2002.
PubMed
12) Yoder BK, Hou X, Guay-Woodford LM, et al:The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol 13:2508-2516. 2002.
 
13) Nauta J, Ozawa Y, Sweeney WE Jr, et al:Renal and biliary abnormalities in a new murine model of autosomal recessive polycystic kidney disease. Pediatr Nephrol 7:163-72, 1993.
 
14) Murcia NS, Richards WG, Yoder BK, et al:The Oak Ridge Polycystic Kidney (orpk) disease gene is required for left-right axis determination. Development 127:2347-2355, 2000.
PubMed
15) Smith UM, Consugar M, Tee LJ, et al:The transmembrane protein meckelin (MKS3) is mutated in Meckel-Gruber syndrome and the wpk rat. Nat Genet 38:191-6, 2006.
PubMed
16) Wang S, Luo Y, Wilson PD, et al:The autosomal recessive polycystic kidney disease protein is localized to primary cilia, with concentration in the basal body area. J Am Soc Nephrol 15:592-602, 2004.
PubMed
17) Menezes LF, Cai Y, Nagasawa Y, et al:Polyductin, the PKHD1 gene product, comprises isoforms expressed in plasma membrane, primary cilium, and cytoplasm. Kidney Int 66:1345-1355, 2004.
PubMed
18) Guay-Woodford LM:Murine models of polycystic kidney disease:molecular and therapeutic insights. Am J Physiol Renal Physiol 285:F1034-1049, 2003.
PubMed
19) Taulman PD, Haycraft CJ, Balkovetz DF, et al:Polaris, a protein involved in left-right axis patterning, localizes to basal bodies and cilia. Mol Biol Cell 12:589-599, 2001.
PubMed
20) Otto EA, Schermer B, Obara T, et al:Mutations in INVS encoding inversin cause nephronophthisis type 2, linking renal cystic disease to the function of primary cilia and left-right axis determination. Nat Genet 34:413-420, 2003.
 
21) Nishio S, Hatano M, Nagata M, et al:Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation. J Clin Invest 115:910-918, 2005.
PubMed
P.49 掲載の参考文献
1) Mizoguchi M, Tamura T, Yamaki A, et al:Genotypes of autosomal dominant polycystic kidney disease in Japanese. J Hum Genet 47:51-54, 2002.
PubMed
2) Rossetti S, Burton S, Stmecki L, et al:The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with severity of renal disease. J Am Soc Nephrol 13:1230-1237, 2002.
 
3) Peltola P, Lumiaho A, Miettinen R, et al:Genetics and phenotypic characteristics of autosomal dominant polycystic kidney disease in Finns. J Mol Med 83:638-646, 2005.
PubMed
4) Rossetti S, Torra R, Coto E, et al:A complete mutation screen of PKHD1 in autosomal-recessive polycystic kidney disease (ARPKD) pedigrees. Kid Int 64:391-403, 2003.
 
5) Takeda S, Takahashi M, Mizukami H, et al:Successful gene transfer using adeno-associated virus vectors into kidney:comparison among adeno-associated virus serotype 1-5 vectors in vitro and in vivo. Nephron Exp Nephrol 96:e119-126, 2004.
PubMed
6) Ito K, Chen J, Asano T, et al:Liposome-mediated gene therapy in the kidney. Hum Cell 17:17-28, 2004.
PubMed
7) Tsujie M, Isaka Y, Nakamura H, et al:Electroporation-mediated gene transfer that targets glomeruli. J Am Soc Nephrol 12:949-954, 2001.
PubMed
8) Imai E, Isaka Y:Perspectives for gene therapy in renal diseases. Int Med 43:85-96, 2004.
 
9) Ricker J, Mata J, Iversen P, et al:C-myc antisense oligonucleotide treatment ameliorates murine ARPKD. Kidney Int 61:S125-S131, 2002.
PubMed
P.62 掲載の参考文献
1) Hughes J, Ward CJ, Peral B, et al:The polycystic kidney disease 1 (PKD1) gene encodes anovel protein with multiple cell recognition domains. Nature Genet 10:151-160, 1995.
 
2) Ward CJ, Turley H, Ong ACM, et al:Polycystin, the polycystic kidney disease 1 protein, is expressed by epithelial cells in fetal, adult, and polycystic kidney. Proc Nat Acad Sci 93:1524-1528, 1996,
 
3) Nauta J, Goedbloed MA, van den Ouweland AM, et al:Immunological detection of polycystin-1 in human kidney. Histochem Cell Biol 113:303-311, 2000.
PubMed
4) Ong AC:Polycystin expression in the kidney and other tissues:complexity, consensus and controversy. Exp Nephrol 8:208-214, 2000.
PubMed
5) Ibraghimov-Beskrovnaya O, Dackowski WR, Foggensteiner L, et al:Polycystin:in vitro synthesis, in vivo tissue expression, and subcellular localization identifies a large membrane-associated protein. Proc Natl Acad Sci USA 94:6397-6402, 1997.
PubMed
6) Peters DJ, van de Wal A, Spruit L, et al:Cellular localization and tissue distribution of polycystin-1. J Pathol 188:439-446, 1999.
PubMed
7) Scheffers MS, van der Bent P, Prins F, et al:Polycystin-1, the product of the polycystic kidney disease 1 gene, co-localizes with desmosomes in MDCK cells. Hum Mol Genet 9:2743-2750, 2000.
PubMed
8) Xu GM, Sikaneta T, Sullivan BM, et al:Polycystin-1 interacts with intermediate filaments. J Biol Chem 276:46544-46545, 2001.
PubMed
9) Huan Y, van Adelsberg J:Polycystin-1, the PKD1 gene product, is in a complex containing E-cadherin and the catenins. J CIin Invest 104:1459-68, 1999.
 
10) Yoder BK, Hou X, Guay-Woodford LM:The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol 13:2508-2516, 2002.
 
11) Hanaoka K, Qian F, Boletta A, et al:Co-assembly of polycystin-1 and-2 produces unique cation-permeable currents. Nature 408:990-994, 2000.
PubMed
12) Grimm DH, Cai Y, Chauvet V, et al:Polycystin-1 distribution is modulated by polycystin-2 expression in mammalian cells. J Biol Chem 278:36786-36793, 2003.
 
13) Kleymenova E, Ibraghimov-Beskrovnaya O, Kugoh H, et al:Tuberin-dependent membrane localization of polycystin-1:a functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Mol Cell 7:823-832, 2001.
PubMed
14) Weston BS, Malhas AN, Price RG:Structure-function relationships of the extracellular domain of the autosomal dominant polycystic kidney disease-associated protein, polycystin-1. FEBS Lett 538:8-13, 2003.
PubMed
15) Malhas AN, Abuknesha RA, Price RG:Interaction of the leucine-rich repeats of polycystin-1 with extracellular matrix proteins:possible role in cell proliferation. J Am Soc Nephrol 13:19-26, 2002.
 
16) Ponting CP, Hofmann K, Bork PA:latrophilin/CL-1-like GPS domain in polycystin-1. Curr Biol 9:R585-588, 1999.
 
17) Lodder AL, Lee TK, Ballester R:Characterization of the Wsc1 protein, a putative receptor in the stress response of Saccharomyces cerevisiae. Genetics 152:1487-1499, 1999.
PubMed
18) The International Polycystic Kidney Disease Consortium:Polycystic kidney disease:the complete structure of the PKD1 gene and its protein. Cell 81:289-98, 1995.
PubMed
19) Gabius HJ:Animal lectins. Eur J Biochem 243:543-576, 1997.
PubMed
20) Weston BS, Bagneris C, Price RG, et al:The polycystin-1 C-type lectin domain bindscarbohydrate in a calcium-dependent manner, and interacts with extracellular matrix proteins in vitro. Biochim Biophys Acta 1536:161-176, 2001.
 
21) Krieger M, Herz J:Structures and functions of multiligand lipoprotein receptors:macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 63:601-637, 1994.
PubMed
22) Sandford R, Sgotto B, Aparicio, et al:Comparative analysis of the polycystic kidney disease 1 (PKD1) gene reveals an integral membrane glycoprotein with multiple evolutionary conserved domains. Hum Mol Genet 6:1483-1489, 1997.
PubMed
23) Bycroft M, Bateman A, Clarke J, et al:The structure of a PKD domain from polycystin-1:implications for polycystic kidney disease. EMBO J 18:297-305, 1999.
PubMed
24) Ibraghimov-Beskrovnaya O, Bukanov NO, Donohue LC, et al:Strong homophilic interactions of the Ig-like domains of polycystin-1, the protein product of an autosomal dominantpolycystic kidney disease gene, PKD1. Hum Mol Genet 9:1641-1649, 2000.
PubMed
25) van Adelsberg J:Peptides from the PKD repeats of polycystin, the PKD1 gene product, modulate pattern formation in the developing kidney. Dev Genet 24:299-308, 1999.
PubMed
26) Moy GW, Mendoza LM, Schulz JR, et al:The sea urchin sperm receptor for egg jelly is a modular protein with extensive homology to the human polycystic kidney disease protein, PKD1. J Cell Biol 133:809-17, 1996.
 
27) Hughes J, Ward CJ, Aspinwall R, et al:Identification of a human homologue of the sea urchin receptor for egg jelly:a polycystic kidney disease-like protein. Hum Mol Genet 8:543-549, 1999.
 
28) Krasnoperov VG, Bittner MA, Beavis R, et al:alpha-Latrotoxin stimulates exocytosis by the interaction with a neuronal G-protein-coupled receptor. Neuron 18:925-937, 1997.
PubMed
29) Qian F, Boletta A, Bhunia AK, et al:Cleavage of polycystin-1 requires the receptor for egg jelly domain and is disrupted by human autosomal-dominant polycystic kidney disease 1-associated mutations. Proc Natl Acad Sci USA 99:16981-16986, 2002.
PubMed
30) Nims N, Vassmer D, Maser RL:Transmembrane domain analysis of polycystin-1, the product of the polycystic kidney disease-1 (PKD1) gene:evidence for 11 membrane-spanning domains. Biochemistry 42:13035-13048, 2003.
PubMed
31) Bateman A, Sandford R:The PLAT domain:a new piece in the PKD1 puzzle. Curr Biol 9:R588-90, 1999.
PubMed
32) Hu J, Barr MM:ATP-2 interacts with the PLAT domain of LOV-1 and is involved in Caenorhabditis elegans polycystin signaling. Mol Biol Cell 16:458-469, 2005.
PubMed
33) Barr MM, Sternberg PW:A polycystic kidney-disease gene homologue required for male mating behavior in C. elegans. Nature 401:386-389, 1999.
 
34) Brown MS, Ye J, Rawson RB, et al:Regulated intramembrane proteolysis:a control mechanism conserved from bacteria to humans. Cell 100:391-398, 2000.
PubMed
35) Urban S, Freeman M:Intramembrane proteolysis controls diverse signalling pathways throughout evolution. Curr Opin Genet Dev 12:512-518, 2002.
PubMed
36) Chauvet V, Tian X, Husson H, et al:Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. J CIin Invest 114:1433-1443, 2004. Erratum in:J Clin Invest 115:788, 2005.
 
37) Guay-Woodford LM:RIP-ed and ready to dance:new mechanisms for polycystin-1 signaling. J CIin Invest 114:1404-1406, 2004.
 
38) Qian F, Germino FJ, Cai Y, et al:PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet 16:179-183, 1997.
PubMed
39) Tsiokas L, Kim E, Arnoul T, et al:Homo-and heterodimeric interactions between the gene products of PKD1 and PKD2. Proc Natl Acad Sci USA 94:6965-6970, 1997.
 
40) Parnell SC, Magenheimer BS, Maser RL, et al:The polycystic kidney disease-1 protein, polycystin-1, binds and activates heterotrimeric G-proteins in vitro. Biochem Biophys Res Commun 251:625-631, 1998.
PubMed
41) Kim E, Arnould T, Sellin LK, et al:The polycystic kidney disease 1 gene product modulates Wnt signaling. J Biol Chem 274:4947-4953, 1999.
PubMed
42) Delmas P, Nomura H, Li X, et al:Constitutive activation of G-proteins by polycystin-1 is antagonized by polycystin-2. J Biol Chem 277:11276-11283, 2002.
PubMed
43) Parnell SC, Magenheimer BS, Maser RL, et al:Polycystin-1 activation of c-Jun N-terminal kinase and AP-1 is mediated by heterotrimeric G proteins. J Biol Chem 277:19566-19572, 2002.
PubMed
44) Puri S, Magenheimer BS, Maser RL, et al:Polycystin-1 activates the calcineurin/NFAT (nuclear factor of activated T-cells) signaling pathway. J Biol Chem 279:55455-55464, 2004.
PubMed
45) Arnould T, Kim E, Tsiokas L, et al:The polycystic kidney disease 1 gene product mediates protein kinase C alpha-dependent and c-Jun N-terminal kinase-dependent activation of the transcription factor AP-1. J Biol Chem 273:6013-6018, 1998.
 
46) Le NH, van der Bent P, Huls G, et al:Aberrant polycystin-1 expression results in modification of activator protein-1 activity, whereas Wnt signaling remains unaffected. J Biol Chem 279:27472-27481, 2004.
PubMed
47) Hang Le N, van der Wal A, van der Bent P, et al:Increased activity of activator protein-1 transcription factor components ATF2, c-Jun, and c-Fos in human and mouse autosomal dominant polycystic kidney disease. J Am Soc Nephrol 16:2724-2731, 2005.
 
48) Kim E, Arnould T, Sellin LK, et al:The polycystic kidney disease 1 gene product modulates Wnt signaling. J Biol Chem 274:4947-4953, 1999.
PubMed
49) Rodova M, Islam MR, Maser RL, et al:The polycystic kidney disease-1 promoter is a target of the beta-catenin/T-cell factor pathway. J Biol Chem 277:29577-29583, 2002.
PubMed
50) Muto S, Aiba A, Saito Y, et al:Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 11:1731-1742, 2002.
PubMed
51) Bhunia AK, Piontek K, Boletta A, et al:PKD1 induces p21 (waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 109:157-168, 2002.
 
52) Sharma M, Brantley JG, Alcalay NI, et al:Differential expression of Cux-1 and p21 in polycystic kidneys from Pkd1 null and cpk mice. Kidney Int 67:432-442, 2005.
PubMed
53) Li X, Luo Y, Starremans PG, et al:Polycystin-1 and polycystin-2 regulate the cell cycle through the helix-loop-helix inhibitor Id2. Nat Cell Biol 7:1102-1112, 2005.
 
54) Kim H, Bae Y, Jeong W, et al:Depletion of PKD1 by an antisense oligodeoxynucleotide induces premature G1/S-phase transition. Eur J Hum Genet 12:433-40, 2004.
 
55) Nishio S, Hatano M, Nagata M, et al:Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation. J Clin Invest 115:910-918, 2005.
PubMed
56) Boletta A, Qian F, Onuchic LF, et al:Polycystin-1, the gene product of PKD1, induces resistance to apoptosis and spontaneous tubulogenesis in MDCK cells. Mol Cell 6:1267-1273, 2000.
PubMed
57) Boca M, Distefano G, Qian F, et al:Polycystin-1 Induces Resistance to Apoptosis through the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway. J Am Soc Nephrol 17:637-47, 2006.
PubMed
58) Kim K, Drummond I, Ibraghimov-Beskrovnaya O, et al:Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci USA 97:1731-1736, 2000.
PubMed
59) Lu W, Shen X, Pavlova A, et al:Comparison of Pkd1-targeted mutants reveals that loss of polycystin-1 causes cystogenesis and bone defects. Hum Mol Genet 10:2385-2396, 2001.
PubMed
60) Boulter C, Mulroy S, Webb S, et al:Cardiovascular, skeletal, and renal defects in mice with atargeted disruption of the Pkd1 gene. Proc Natl Acad Sci USA 98:12174-12179, 2001.
 
61) Kim H, Jeong W, Ahn K, et al:Siah-1 interacts with the intracellular region of polycystin-1 and affects its stability via the ubiquitin-proteasome pathway. J Am Soc Nephrol 15:2042-2049, 2004.
 
62) Barr MM, DeModena J, Braun D, et al:The Caenorhabditis elegans autosomal dominant polycystic kidney disease gene homologs lov-1 and pkd-2 act in the same pathway. Curr Biol 11:1341-1346, 2001.
PubMed
63) Yuasa T, Venugopal B, Weremowicz S, et al:The sequence, expression, and chromosomal localization of a novel polycystic kidney disease 1-like gene, PKD1L1, in human. Genomics 79:376-386, 2002.
PubMed
64) Li A, Tian X, Sung SW, et al:Identification of two novel polycystic kidney disease-1-like genes in human and mouse genomes. Genomics 81:596-608, 2003. Erratum in:Genomics 82:498-500, 2003.
 
65) Yuasa T, Takakura A, Denker BM, et al:Polycystin-1L2 is a novel G-protein-binding protein. Genomics 84:126-38, 2004.
 
P.70 掲載の参考文献
1) Mochizuki T, Wu G, Hayashi T, et al:PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272:1339-42, 1996.
PubMed
2) Nomura H, Turco AE, Pei Y, et al:Identification of PKDL, a novel polycystic kidney disease 2-like gene whose murine homologue is deleted in mice with kidney and retinal defects. J Biol Chem 273:25967-25973, 1998.
PubMed
3) Nilius B, Voets T:TRP channels:a TR (I) P through a world of multifunctional cation channels. Pflugers Arch 451:1-10, 2005.
 
4) Ong ACM, Ward CJ, Butler RJ, et al:Coordinate expression of the autosomal dominant polycystic kidney disease proteins, polycystin-2 and polycystin-1, in normal and cystic tissue. Am J Pathol 154:1721-1729, 1999.
 
5) Obermuller N, Gallagher AR, Cai Y, et al:The rat pkd2 protein assumes distinct subcellular distributions in different organs. Am J Physiol 277:F914-F925, 1999.
PubMed
6) Yoder BK, Hou X, Guay-Woodford LM:The Polycystic Kidney Disease Proteins, Polycystin-1, Polycystin-2, Polaris, and Cystin, Are Co-Localized in Renal Cilia. J Am Soc Nephrol 13:2508-2516, 2002.
 
7) N Obermuller N, Cai Y, Kranzlin B, et al:Altered Expression Pattern of Polycystin-2 in Acute and Chronic Renal Tubular Diseases. J Am Soc Nephrol 13:1855-1864, 2002.
 
8) Tsiokas L, Arnould T, Zhu C, et al:Homo-and heterodimeric interactions between the gene products of PKD1 and PKD2. Proc Natl Acad Sci USA 94:6965-6970, 1997.
 
9) Qian F, Germino FJ, Cai Y, et al:PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet 16:179-183, 1997.
PubMed
10) Kottgen M, Benzing T, Simmen T, et al:Trafficking of TRPP2 by PACS proteins represents a novel mechanism of ion channel regulation. EMBO J 24:705-716, 2005.
PubMed
11) Guo L, Schreiber TH, Weremowicz S, et al:Identification and characterization of a novel polycystin family member, polycystin-L2, in mouse and human:sequence, expression, alternative splicing, and chromosomal localization. Genomics 64:241-251, 2000.
PubMed
12) Hardie RC, Minke B:The trp gene is essential for a light-activated Ca2+ channel in Drosophila photoreceptors. Neuron 8:643-651, 1992.
PubMed
13) Wes PD, Chevesich J, Jeromin A, et al:TRPC1, a human homolog of a Drosophila store-operated channel. Proc Natl Acad Sci USA 92:9652-9656, 1995.
PubMed
14) Montell C, Birnbaumer L, Flockerzi V:The TRP channels, a remarkably functional family. Cell 108:595-598, 2002.
PubMed
15) Hanaoka K, Qian F, Boletta A, et al:Co-assembly of polycystin-1 and-2 produces unique cation-permeable currents. Nature 408:990-994, 2000.
PubMed
16) Chen XZ, Vassilev PM, Basora N, et al:Polycystin-L is a calcium-regulated cation channel permeable to calcium ions. Nature 401:383-386, 1999.
 
17) Arnould T, Kim E, Tsiokas L, et al:The polycystic kidney disease 1 gene product mediates protein kinase C alpha-dependent and c-Jun N-terminal kinase-dependent activation of the transcription factor AP-1. J Biol Chem 273:6013-6018, 1998.
 
18) Arnould T, Sellin L, Benzing T, et al:Cellular activation triggered by the autosomal dominant polycystic kidney disease gene product PKD2. Mol Cell Biol 19:3423-3434, 1999.
 
19) Kim E, Arnould T, Sellin LK, et al:The polycystic kidney disease 1 gene product modulates Wnt signaling. J Biol Chem 274:4947-4953, 1999.
PubMed
20) Bhunia AK, Piontek K, Boletta A, et al:PKD1 induces p21 (waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 109:157-168, 2002.
 
21) Chauvet V, Tian X, Husson H, et al:Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. J Clin Invest 114:1433-1443, 2004.
PubMed
22) Geng L, Burrow CR, Li HP, et al:Modification of the composition of polycystin-1 multiprotein complexes by calcium and tyrosine phosphorylation. Biochim Biophys Acta 1535:21-35, 2000.
PubMed
23) Gallagher AR, Cedzich A, Gretz N, et al:The polycystic kidney disease protein PKD2 interacts with Hax-1, a protein associated with the actin cytoskeleton. Proc Natl Acad Sci USA 97:4017-4022, 2000.
PubMed
24) Li Q, Dai Y, Guo L, et al:Polycystin-2 associates with tropomyosin-1, an actin microfilament component. J Mol Biol 325:949-962, 2003.
PubMed
25) Li Q, Shen PY, Wu G, et al:Polycystin-2 interacts with troponin I, an angiogenesis inhibitor. Biochemistry 42:450-457, 2003.
 
26) Li Q, Liu Y, Shen PY, et al:Troponin I binds polycystin-L and inhibits its calcium-induced channel activation. Biochemistry 42:7618-7625, 2003.
 
27) Li Q, Liu Y, Zhao W, et al:The calcium-binding EF-hand in polycystin-L is not a domain for channel activation and ensuing inactivation. FEBS Lett 516:270-278, 2002.
 
28) Cai Y, Maeda Y, Cedzich A, et al:Identification and characterization of polycystin-2, the PKD2 gene product. J Biol Chem 274:28557-28565, 1999.
PubMed
29) Vassilev PM, Gou L, Chen XZ, et al:Polycystin-2 is a novel cation channel implicated in defective intracellular Ca2+ homeostasis in polycystic kidney disease. Biochem Biophys Res Commun 282:341-350, 2001.
 
30) Koulen P, Cai Y, Geng L, et al:Polycystin-2 is an intracellular calcium release channel Nat Cell Biol 4:191-197, 2002.
PubMed
P.76 掲載の参考文献
1) Tsiokas L, Arnould T, Zhu C, et al:Homo-and heterodimeric interactions between the gene products of PKD1 and PKD2. Proc Natl Acad Sci USA 94:6965-6970, 1997.
 
2) Qian F, Germino FJ, Cai Y, et al:PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet 16:179-183, 1997.
PubMed
3) Gonzalez-Perrett S, Batelli M, Kim K, et al:Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca2+-permeable nonselective cation channel. Proc Natl Acad Sci USA 98:1182-1187, 2001.
PubMed
4) Vassilev PM, Gou L, Chen XZ, et al:Polycystin-2 is a novel cation channel implicated in defective intracellular Ca2+ homeostasis in polycystic kidney disease. Biochem Biophys Res Commun 282:341-350, 2001.
 
5) Koulen P, Cai Y, Geng L, et al:Polycystin-2 is an intracellular calcium release channel. Nat Cell Biol 4:191-197, 2002.
PubMed
6) Chen XZ, Segal Y, Basora N, et al:Transport function of the naturally occurring pathogenic polycystin-2 mutant, R742X. Biochem Biophys Res Commun 282:1251-1256, 2001.
PubMed
7) Cantiello HF:Regulation of calcium signaling by polycystin-2. Am J Physiol 286:F1012-F1029, 2004.
 
8) Hanaoka K, Qian F, Boletta A, et al:Co-assembly of polycystin-1 and-2 produces unique cation-permeable currents. Nature 408:990-994, 2000.
PubMed
9) Yoder BK, Hou X, Guay-Woodford LM:The Polycystic Kidney Disease Proteins, Polycystin-1, Polycystin-2, Polaris, and Cystin, Are Co-Localized in Renal Cilia. J Am Soc Nephrol 13:2508-2516, 2002.
 
10) Nauli SM, Alenghat FJ, Luo Y, et al:Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 33:129-137, 2003.
PubMed
11) Grimm DH, Cai Y, Chauvet V, et al:Polycystin-1 distribution is modulated by polycystin-2 expression in mammalian cells. J Biol Chem 278:36786-36793, 2003.
 
12) Chauvet V, Tian X, Husson H, et al:Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. J Clin Invest 114:1433-1443, 2004.
PubMed
P.86 掲載の参考文献
1) Peters DJM, Breuning MH:Autosomal dominant polycystic kidney disease:Modification of disease progression. Lancet 358:1439-1444, 2001.
 
2) Torra R, Badenas C, Darnell A, et al:Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2. J Am Soc Nephrol 7:2142-2151, 1996.
PubMed
3) Hateboer N, Dijk MA, Bogdanova N, et al:Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 353:103-107, 1999.
 
4) Johnson AM, Gabow PA:Identification of Patients with Autosomal Dominant Polycystic Kidney Disease at Highest Risk for End-Stage Renal Disease. J Am Soc Nephrol 8:1560-1567, 1997.
PubMed
5) Rossetti S, Burton S, Strmecki L, et al:The Position of the Polycystic Kidney Disease 1 (PKD1) Gene Mutation Correlates with the Severity of Renal Disease. J Am Soc Nephrol 13:1230-1237, 2002.
PubMed
6) Magistroni R, He N, Wang K, et al:Genotype-Renal Function Correlation in Type 2 Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 14:1164-1174, 2003.
PubMed
7) Fain PR, McFann KK, Taylor MRG, et al:Modifier genes play a significant role in the phenotypic expression of PKD1. Kidney International 67:1256-1267, 2005.
PubMed
8) Nadeau JH:Modifier genes in mice and humans. Nat Rev Genet 2:165-174, 2001.
PubMed
9) Woo DD, Nguyen DK, Khatibi N, et al:Genetic identification of two major modifier loci of polycystic kidney disease progression in pcy mice. J Clin Invest 100:1934-1940, 1997.
 
10) Kuida S, Beier DR:Genetic localization of interacting modifiers affecting severity in a murine model of polycystic kidney disease. Genome Res 10:49-54, 2000.
 
11) Muto S, Horie S:personal communication.
 
12) Peral B, Ong ACM, San Millan JL, et al:Astable, nonsense mutation associated with a case of infantile onset polycystic kidney disease 1 (PKD1). Hum Mol Genet 5:539-542, 1996.
 
13) Choukroun G, Itakura Y, Albouze G, et al:Factors influencing progression of renal failure in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 6:1634-1642, 1995.
PubMed
14) Geberth S, Stier E, Zeier M, et al:More adverse renal prognosis of autosomal dominant polycystic kidney disease in families with primary hypertension. J Am Soc Nephrol 6:1643-1648, 1995.
PubMed
15) Barrett BJ, Foley R, Morgan J, et al:Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. Kidney Int 46:1118-1123, 1994.
PubMed
16) Chapman AB, Johnson A, Gabow PA, et al:The reninangiotensin-aldosterone system and autosomal dominant polycystic kidney disease [see comments]. N Engl J Med 323:1091-1096, 1999.
 
17) Torres VE, Wilson DM, Burnett J Jr, et al:Effect of inhibition of converting enzyme onrenal hemodynamics and sodium management in polycystic kidney disease. Mayo Clin Proc 66:1010-1017, 1991.
 
18) Jeunemaitre X, Soubrier F, Kotelevtsev Y, et al:Molecular basis of human hypertension:role of angiotensinogen. Cell 71:169-180, 1992.
PubMed
19) Tiret L, Rigat B, Viskivis S, et al:Evidence from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) controls plasma ACE levels. Am J Hum Genet 51:197-205, 1992.
PubMed
20) Ruiz J, Blanche H, Cohen N, et al:Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 91:3662-3665, 1994.
PubMed
21) Raynolds MV, Bristow MR, Bush E, et al:Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 342:1073-1075, 1993.
PubMed
22) Yoshida H, Mitarai T, Kawamura T, et al:Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 96 (5):2162-9, Nov, 1995.
PubMed
23) Baboolal K, Ravine D, Daniels J, et al:Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease. Kidney Int 52:607-613, 1997.
PubMed
24) Perez-Oller L, Torra R, Bandenas C, et al:Influence of the angiotensin converting enzyme polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease. Am J Kidney Dis 34:273-278, 1999.
 
25) van Dijk MA, Breuning MH, Peters DJ, et al:The ACE insertion/deletion polymorphism has no influence on progression of renal function loss in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 15:836-839, 2000.
PubMed
26) Schiavello T, Burke V, Bogdanova N, et al:Angiotensin-converting enzyme activity and the ACE Alu polymorphism in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 16:2323-2327, 2001.
PubMed
27) Sullivan LP, Wallace DP, Grantham JJ:Epithelial transport in polycystic kidney disease. Physiol Rev 78:1165-1191, 1998.
PubMed
28) O'Sullivan DA, Torres VE, Gabow PA, et al:Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis 32:976-983, 1998.
PubMed
29) Persu A, Devuyst O, Lannoy N, et al:CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 11:2285-2296, 2000.
PubMed
30) Torres VE, Cai Y, Chen X, et al:Vascular expression of polycystin-2. J Am Soc Nephrol 12:1-9, 2001.
 
31) Chauvet V, Qian F, Boute N, et al:Expression of PKD1 and PKD2 transcripts and proteins in human embryo and during normal kidney development. Am J Pathol 160:973-983, 2002.
PubMed
32) Kim K, Drummond I, Ibraghimov-Beskrovnaya O, et al:Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci USA 97:1731-1736, 2000. [Boulter C, Mulroy S, Webb S, et al:Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene. Proc Natl Acad Sci USA 98:12174-12179, 2001. ]
 
33) Muto S, Aiba A, Saito Y, et al:Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 11:1731-1742, 2002.
PubMed
34) Wang D, Iversen J, Strandgaard S:Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 11:1371-1376, 2000.
PubMed
35) Wang D, Iversen J, Strandgaard S:Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 11:1371-1376, 2000.
PubMed
36) Zanchi A, Moczulski DK, Hanna LS, et al:Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int 57:405-413, 2000.
PubMed
37) Noiri E, Satoh H, Taguchi J, et al:Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension 40:535-540, 2002.
PubMed
38) Persu A, Stoenoiu MS, Messiaen T, et al:Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 11:229-241, 2002.
PubMed
39) Mendelsohn ME, Karas RH:The protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801-1811, 1999.
PubMed
40) Walker D, Consugar M, Slezak J, et al:The ENOS polymorphism is not associated with severity of renal disease in polycystic kidney disease 1. Am J Kidney Dis 41:90-94, 2003.
 
41) Casas JP, Bautista LE, Humphries SE, et al:Endothelial Nitric Oxide Synthase Genotype and Ischemic Heart Disease:Meta-Analysis of 26 Studies Involving 23028 Subjects Circulation 109 (11):1359-1365, March 23, 2004.
 
P.100 掲載の参考文献
1) Knudson AG:Mutation and cancer:statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-82, 1971.
PubMed
2) Cavenee WK, Dryja TP, Phillips RA, et al:Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305:779-84, 1983.
PubMed
3) Qian F, Germino GG:"Mistakes happen":somatic mutation and disease. Am J Hum Genet 61:1000-1005, 1997.
PubMed
4) Qian F, Watnick TJ, Onuchic LF, et al:The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 87:979-987, 1996.
PubMed
5) Brasier JL, Henske EP:Loss of the polycystic kidney disease (PKD1) region of chromosome 16p13 in renal cyst cells supports a loss-of-function model for cyst pathogenesis. J Clin Invest 99:194-199, 1997.
PubMed
6) Lu W, Peissel B, Babakhanlou H, et al:Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkdl mutation. Nat Genet 17:179-181, 1997.
 
7) Lu W, Fan X, Basora N, et al:Late onset of renal and hepatic cysts in Pkd1-targeted heterozygotes. Nat Genet 21:160-161, 1999.
PubMed
8) Boulter C, Mulroy S, Webb S, et al:Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene. Proc Natl Acad Sci USA 98:12174-12179, 2001.
PubMed
9) Kim K, Drummond I, Ibraghimov-Beskrovnaya O, et al:Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci USA 97:1731-1736, 2000.
PubMed
10) Lu W, Shen X, Pavlova A, et al:Comparison of Pkd1-targeted mutants reveals that loss of polycystin-1 causes cystogenesis and bone defects. Hum Mol Genet 10:2385-2396, 2001.
PubMed
11) Muto S, Aiba A, Saito Y, et al:Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 11:1731-1742, 2002.
PubMed
12) Wu G, D'Agati, Cai Y, et al:Somatic inactivation of pkd2 results in polycystic kidney disease. Cell 93:177-188, 1998.
 
13) Wu G, Markowitz GS, Li L, et al:Cardiac defects and renal failure in mice with targeted mutations in Pkd2. Nat Genet 24:75-78, 2000.
PubMed
14) Colgin LM, Hackmann AF, Emond MJ, et al:The unexpected landscape of in vivo somatic mutation in a human epithelial cell lineage. Proc Natl Acad Sci USA 99:1437-1442, 2002.
 
15) Patel HP, Lu L, Blaszak RT, et al:PKD1 intron 21:triplex DNA formation and effect on replication. Nucleic Acids Res 32:1460-1468, 2004.
PubMed
16) Watnick TJ, Gandolph MA, Weber H, et al:Gene conversion is a likely cause of mutation in PKD1. Hum Mol Genet 7:1239-43, 1998.
PubMed
17) Nishio S, Hatano M, Nagata M, et al:Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation. J Clin Invest 115:910-918, 2005.
PubMed
18) Qian Q, Hunter LW, Li M, et al:Pkd2 haploinsufficiency alters intracellular calcium regulation in vascular smooth muscle cells. Hum Mol Genet 12:1875-80, 2003.
PubMed
19) Watnick T, He N, Wang K, et al:Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of trans-heterozygous mutations. Nat Genet 25:143-144, 2000.
PubMed
20) Koptides M, Mean R, Demetriou K, et al:Genetic evidence for a trans-heterozygous model for cystogenesis in autosomal dominant polycystic kidney disease. Hum Mol Genet 9:447-452, 2000.
PubMed
21) Wu G, Tian X, Nishimura S, et al:Trans-heterozygous Pkd1 and Pkd2 mutations modify expression of polycystic kidney disease. Hum Mol Genet 11:1845-1854, 2002.
PubMed
22) Lantinga-van Leeuwen IS, Dauwerse JG, Baelde HJ, et al:Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease. Hum Mol Genet 13:3069-3077, 2004.
PubMed
23) Jiang ST, Chiou YY, Wang E, et al:Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of pkd1. Am J Pathol 168:205-220, 2006.
PubMed
24) The Europian Polycystic Kidney Disease Consortium:Polycystic idney disease 1 gene encodes a 14kb trnscript and lies within a duplicated region on chromosome 16. Cell 77:881-894, 1994.
 
25) Ong AC:Polycystin expression in the kidney and other tissues:complexity, consensus and controversy. Exp Nephrol 8:208-214, 2000.
PubMed
26) Nauta J, Goedbloed MA, van den Ouweland AM, et al:Immunological detection of polycystin-1 in human kidney. Histochem Cell Biol 113:303-311, 2000.
PubMed
27) Pritchard L, Sloane-Stanley JA, Sharpe JA, et al:A human PKD1 transgene generates functional polycystin-1 in mice and is associated with a cystic phenotype. Hum Mol Genet 9:2617-2627, 2000.
PubMed
28) Thivierge C, Kurbegovic A, Couillard M, et al:Overexpression of PKD1 Causes Polycystic Kidney Disease. Mol Cell Biol 26:1538-1548, 2006.
PubMed
29) Brook-Carter PT, Peral B, Ward CJ, et al:Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease:a contiguous gene syndrome. Nat Genet 8:328-332, 1994.
PubMed
30) Eker R:Familial renal adenomas in Wistar rats:a preliminary report. Acta Path Microbiol Scand 34:554-562, 1954.
PubMed
31) Eker R, Mosslge JA:A dominant gene for renal adenomas in the rats. Nature 189:858-859, 1961.
 
32) Yeung RS, Xiao GH, Jin F, et al:Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc Natl Acad Sci USA 91:11413-11416, 1994.
PubMed
33) Kobayashi T, Hirayama Y, Kobayashi E, et al:A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat Genet 9:70-74, 1995.
 
34) Kleymenova E, Ibraghimov-Beskrovnaya O, Kugoh H, et al:Tuberin-dependent membrane localization of polycystin-1:a functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Mol Cell 7:823-832, 2001.
PubMed
35) Cai S, Everitt JI, Kugo H, et al:Polycystic kidney disease as a result of loss of the tuberous sclerosis 2 tumor suppressor gene during development. Am J Pathol 162:457-468, 2003.
PubMed
36) ヒトの分子遺伝学. 村松正實監修, メディカル・サイエンス・インターナショナル, 東京, 1997.
 
P.109 掲載の参考文献
1) Lubarsky B, Krasnow MA:Tube morphogenesis:making and shaping biological tubes. Cell 112:19-28, 2003.
 
2) Montesano R, Matsumoto K, Nakamura T, et al:Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67:901-908, 1991.
PubMed
3) Montesano R, Schaller G, Orci L:Induction of epithelial tubular morphogenesis in vitro by fibroblast-derived soluble factors. Cell 66:697-711, 1991.
PubMed
4) Pollack AL, Runyan RB, Mostov KE:Morphogenetic mechanisms of epithelial tubulogenesis:MDCK cell polarity is transiently rearranged without loss of cell-cell contact during scatter factor/hepatocyte growth factor-induced tubulogenesis. Dev Biol 204:64-79, 1998.
PubMed
5) O'Brien LE, Zegers MM, Mostov KE:Opinion:Building epithelial architecture:insights from three-dimensional culture models. Nat Rev Mol Cell Biol 3:531-537, 2002.
PubMed
6) Vega-Salas DE, Salas PJ, Rodriguez-Boulan E:Modulation of the expression of an apical plasma membrane protein of Madin-Darby canine kidney epithelial cells:cell-cell interactions control the appearance of a novel intracellular storage compartment. J Cell Biol 104:1249-1259, 1987.
PubMed
7) Vega-Salas DE, Salas PJ, Rodriguez-Boulan E:Exocytosis of vacuolar apical compartment (VAC):a cell-cell contact controlled mechanism for the establishment of the apical plasma membrane domain in epithelial cells. J Cell Biol 107:1717-1728, 1988.
PubMed
8) Buechner M:Tubes and the single C. elegans excretory cell. Trends Cell Biol 12:479-484, 2002.
PubMed
9) Buechner M, Hall DH, Bhatt H, et al:Cystic canal mutants in Caenorhabditis elegans are defective in the apical membrane domain of the renal (excretory) cell. Dev Biol 214:227-241, 1999.
PubMed
10) McKeown C, Praitis V, Austin J:sma-1 encodes a betaH-spectrin homolog required for Caenorhabditis elegans morphogenesis. Development 125:2087-2098, 1998.
PubMed
11) Suzuki N, Buechner M, Nishiwaki K, et al:A putative GDP-GTP exchange factor is required for development of the excretory cell in Caenorhabditis elegans. EMBO Rep 2:530-535, 2001.
PubMed
12) Jones SJ, Baillie DL:Characterization of the let-653 gene in Caenorhabditis elegans. Mol Gen Genet 248:719-726, 1995.
PubMed
13) Gallagher AR, Obermuller N, Cedzich A, et al:An ever-expanding story of cyst formation. Cell Tissue Res 300:361-371, 2000.
PubMed
14) Yoder BK, Hou X, Guay-Woodford LM:The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am SocNephrol 13:2508-2516, 2002.
 
15) Nauli SM, Alenghat FJ, Luo Y, et al:Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 33:129-137, 2003.
PubMed
16) Nickel C, Benzing T, Sellin L, et al:The polycystin-1 C-terminal fragment triggers branching morphogenesis and migration of tubular kidney epithelial cells. J Clin Invest 109:481-489, 2002.
PubMed
17) Boletta A, Qian F, Onuchic LF, et al:Polycystin-1, the gene product of PKD1, inducesresistance to apoptosis and spontaneous tubulogenesis in MDCK cells. Mol Cell 6:1267-1273, 2000.
PubMed
18) Polgar K, Burrow CR, Hyink DP, et al:Disruption of polycystin-1 function interferes with branching morphogenesis of the ureteric bud in developing mouse kidneys. Dev Biol 286:16-30, 2005.
PubMed
19) Grimm DH, Karihaloo A, Cai Y, et al:Polycystin-2 regulates proliferation and branchingmorphogenesis in kidney epithelial cells. J Biol Chem 281:137-44, 2006.
 
20) Geng L, Segal Y, Pavlova A, et al:Distribution and developmentally regulated expression of murine polycystin. Am J Physiol 272:F451-459, 1997.
PubMed
21) Markowitz GS, Cai Y, Li L, et al:Polycystin-2 expression is developmentally regulated. Am J Physiol 277:F17-25, 1999.
 
22) Fischer E, Legue E, Doyen A, et al:Defective planar cell polarity in polycystic kidney disease. Nat Genet 38:21-23, 2006.
PubMed
P.118 掲載の参考文献
1) Ibanez-Tallon I, Heintz N, Omran H:To beat or not to beat:roles of cilia in development and disease. Hum Mol Genet 12:R27-R35, 2003.
PubMed
2) Rosenbaum JL, Witman GB:Intraflagellar transport. Nat Rev Mol Cell Biol 3:813-825, 2002.
PubMed
3) Supp DM, Witte DP, Potter SS, et al:Mutation of an axonemal dynein affects left-right asymmetry in inversus viscerum mice. Nature 389:963-966, 1997.
PubMed
4) Pazour GJ, Dickert BL, Vucica Y, et al:Chlamydomonas IFT88 and its mouse homologue, polycystic kidney disease gene tg737, are required for assembly of cilia and flagella. J Cell Biol 151:709-718, 2000.
PubMed
5) Lin F, Hiesberger T, Cordes K, et al:Kidney-specific inactivation of the KIF3A subunit of kinesin-II inhibits renal ciliogenesis and produces polycystic kidney disease. Proc Natl Acad Sci USA 100:5286-5291, 2003.
PubMed
6) Barr MM, Sternberg PW:A polycystic kidney-disease gene homologue required for male mating behaviour in C. elegans. Nature 401:386-389, 1999.
 
7) Barr MM, DeModena J, Braun D, et al:The Caenorhabditis elegans autosomal dominant polycystic kidney disease gene homologs lov-1 and pkd-2 act in the same pathway. Curr Biol 11:1341-1346, 2001.
PubMed
8) Pazour GJ, San Agustin JT, Follit JA, et al:Polycystin-2 localizes to kidney cilia and the ciliary level is elevated in orpk mice with polycystic kidney disease. Curr Biol 12:R378-R380, 2002.
PubMed
9) Yoder BK, Hou X, Guay-Woodford LM:The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol 13:2508-2516, 2002.
 
10) Ward CJ, Yuan D, Masyuk TV, et al:Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia. Hum Mol Genet 12:2703-2710, 2003.
PubMed
11) Masyuk TV, Huang BQ, Ward CJ, et al:Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat. Gastroenterology 125:1303-1310, 2003,
PubMed
12) Praetorius HA, Spring KR:A physiological view of the primary cilium. Annu Rev Physiol 67:515-529, 2005.
PubMed
13) Paetorius HA, Spring KR:Bending the MDCK cell primary cilium increases intracellular calcium. J Membr Biol 184:71-79, 2001.
 
14) Nauli SM, Alenghat FJ, Luo Y, et al:Polycystins l and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 33:129-137, 2003.
 
15) Parnell SC, Magenheimer BS, Maser RL, et al:Polycystin-1 activation of c-Jun N-terminal kinase and AP-1 is mediated by heterotrimeric G proteins. J Biol Chem 277:19566-19572, 2002.
PubMed
16) Chauvet V, Xin T, Husson H, et al:Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. J Clin Invest 114:1433-1443, 2004.
 
17) Mochizuki T, Saijoh Y, Tsuchiya K, et al:Cloning of inv, a gene that controls left/right asymmetry and kidney development. Nature 395:177-181, 1998.
PubMed
18) Ward CJ, Yuan D, Masyuk TV, et al:Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia. Hum Mol Genet 12:2703-2710, 2003.
PubMed
19) Otto EA, Schermer B, Obara T, et al:Mutations in INVS encoding inversin cause nephronophtihisis type 2, linking renal cystic disease to the function of primary cilia and left-right axis determination. Nat Genet 34:413-420, 2003.
 
20) Otto EA, Loeys B, Khanna H, et al:Nephrocystin-5, a ciliary IQ domain protein, is mutated in Senior-Loken syndrome and interacts with RPGR and calmodulin. Nat Genet 37:282-288, 2005.
PubMed
21) Katsanis N:The oligogenic properties of Bardet-Biedl syndrome. Hum Mol Genet 13:R65-R71, 2004.
PubMed
22) Romio L, Fry AM, Winyard PJ, et al:OFDI is a centrosomal/basal body protein expressed during mesenchymal-epithelial transition in human nephrogenesis, J Am Soc Nephrol 15:2556-2568, 2004.
 
P.126 掲載の参考文献
1) Yamaguchi T, et al:Kidney Int 57:1460-71, 2000.
PubMed
2) Hanaoka K, Guggino WB:J Am Soc Nephrol 11:1179-87, 2000.
 
3) Sutters M, et al:Kidney Int 60:484-71, 2001.
PubMed
4) Yamaguchi T, et al:J Biol Chem 279:40419-30, 2004.
PubMed
5) Yamaguchi T, Nagao S, et al:Kidney Int 63:1983-94, 2003.
PubMed
6) Nagao S, et al:Kidney Int 63:427-37, 2003.
PubMed
7) Yamaguchi T, et al:J Am Soc Nephrol 17:178-87, 2006.
PubMed
8) Nutahara K, et al:Nephron Clin Pract 99:18-23, 2005.
 
9) Nishii K, et al:J Am Soc Nephrol 16:363A (Abstract PO114), 2005.
 
10) Yamaguchi T, et al:J Am Soc Nephrol 16:587A (Abstract PO125), 2005.
 
11) Gattone VH, et al:Nat Med 9:1323-6, 2003.
PubMed
12) Torres VE, et al:Nat Med 10:363-4, 2004.
PubMed
13) Nagao S, et al:J Am Soc Nephrol 16:362A (Abstract PO109), 2005.
 
14) Ye M, Grantham JJ:N Engl J Med 329:310-13, 1992.
 
15) Putnam WC, et al:J Am Soc Nephrol 16:362A (Abstract PO110), 2005.
 
16) Klingel R, et al:Am J Kidney Dis 19:22-30, 1992.
 
17) Sweeney WE, Avner ED:Am J Physiol 275:F387-94, 1998.
PubMed
18) Sweeney WE, et al:Kidney Int 57:33-40, 2000.
PubMed
19) Awazu M, et al:J Am Soc Nephrol 16:362A (Abstract PO112), 2005.
 
20) Aukema HM, et al:Kidney Int 59:52-61, 2001.
PubMed
21) Kim K, et al:Proc Natl Acad Sci USA 97:1731-6, 2000.
PubMed
22) Bolleta A, et al:Mol Cell 6:1267-73, 2000.
PubMed
23) Bhunia AK, et al:Cell 109:157-68, 2002.
PubMed
24) Kim E, et al:J Biol Chem 274:4947-53, 1999.
 
25) Rotibak T, et al:Mol Cell Biol 15:1334-46, 2004.
 
26) Muto S, et al:Hum Mol Genet 11:1731-42, 2002.
PubMed
27) Lanoix J, et al:Oncogene 13:1153-60, 1996.
PubMed
28) Cowley BD Jr, et al:Proc Natl Acad Sci USA 84:8394-8, 1987.
PubMed
29) Cowley BD Jr, et al:Kidney Int 43:522-34, 1993.
PubMed
30) Trudel M, et al:J Exp Med 186:1873-84, 1997.
 
31) Veis DJ, et al:Cell 75:229-40, 1993.
PubMed
32) Woo D:N Engl J Med 333:18-25, 1995.
PubMed
33) Tao Y, et al:Proc Natl Acad Sci USA 102:6954-9, 2005.
PubMed
34) Bello-Reuss E, et al:Kidney Int 60:37-45, 2001.
PubMed
35) Wilhelm SM, et al:Cancer Res 64:7099-109, 2004.
PubMed
36) Ubara Y, et al:Am J Kidney Dis 34:926-31, 1999.
PubMed
37) Ubara Y, et al:Am J Kidney Dis 39:571-9, 2002.
PubMed
P.130 掲載の参考文献
1) Welsh MJ, Fick RB:Cystic fibrosis. J Clin Invest 80:1523-1526, 1987.
PubMed
2) Wine JJ:The genesis of cystic fibrosis lung disease. J Clin Invest 103:309-312, 1999.
 
3) Sheppard DN, Welsh MJ:Structure and function of the CFTR chloride channel. Physiol Rev 79:S23-45, 1999.
PubMed
4) Riordan JR:Assembly of functional CFTR chloride channels. Annu Rev Physiol 67:701-718, 2005.
PubMed
5) Perrone RD:In vitro function of cyst epithelium from human polycystic kidney. J Clin Invest 76:1688-91, 1985.
PubMed
6) Ye M, Grantham JJ:The secretion of fluid by renal cysts from patients with autosomal dominant polycystic kidney disease. N Engl J Med 329:310-313, 1993.
PubMed
7) Hanaoka K, Devuyst O, Schwiebert EM, et al:A role for CFTR in human autosomal dominant polycystic kidney disease. Am J Physiol 270:C389-99, 1996.
PubMed
8) Mangoo-Karim R, Ye M, Wallace DP, et al:Anion secretion drives fluid secretion by monolayers of cultured human polycystic cells. Am J Physiol 269:F381-F388, 1995.
PubMed
9) Davidow CJ, Maser RL, Rome LA, et al:The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro. Kidney Int 50:208-218, 1996.
PubMed
10) Hanaoka K, Guggino WB:cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 11:1179-1187, 2000.
 
11) Yamaguchi T, Pelling JC, Ramaswamy NT, et al:cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 57:1460-1471, 2000.
PubMed
12) Nagao S, Yamaguchi T, Kusaka M, et al:Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease. Kidney Int 63:427-437, 2003.
PubMed
13) Wilson PD:Epithelial cell polarity and disease. Am J Physiol 272:F434-F442, 1997.
PubMed
14) Wilson PD, Sherwood AC, Palla K, et al:Reversed polarity of Na (+)-K (+)-ATPase:mislocation to apical plasma membranes in polycystic kidney disease epithelia. Am J Physiol 260:F420-F430, 1991.
PubMed
15) Du J, Wilson PD:Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD. Am J Physiol 269:C487-95, 1995.
PubMed
16) Rocco MV, Neilson EG, Hoyer JR, et al:Attenuated expression of epithelial cell adhesion molecules in murine polycystic kidney disease. Am J Physiol 262:F679-F686, 1992.
PubMed
17) Lebeau C, Hanaoka K, Moore-Hoon ML, et al:Basolateral chloride transporters in autosomal dominant polycystic kidney disease. Pflugers Arch 444:722-31, 2002.
PubMed
18) Ogborn MR, Sareen S, Tomobe K, et al:Renal tubule Na, K-ATPase polarity in different animal models of polycystic kidney disease. J Histochem Cytochem b43:785-90, 1995.
 
19) Richards WG, Sweeney WE, Yoder BK, et al:Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J Clin Invest 101:935-9, 1998.
PubMed
20) O'Sullivan DA, Torres VE, Gabow PA, et al:Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney diease. Am J Kidney Dis 32:976-983, 1998.
 
21) Persu A, Devuyst O, Lannoy N, et al:CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 11:2285-2296, 2000.
PubMed
P.137 掲載の参考文献
1) Ong ACM, Harris PC:Molecular pathogenesis of ADPKD:The polycystin complex gets complex. Kidney Int 67:1234-1247, 2005.
PubMed
2) Nakamura T, Ebihara I, Nagaoka I, et al:Growth factor gene expression in kidney of murine polycystic kidney disease. J Am Soc Nephrol 3:1378-1386, 1993.
PubMed
3) Ebihara I, Nakamura T, Takahashi T, et al:Altered extracellular matrix component gene expression in murine polycystic kidney. Renal Physiol Biochem 18:73-80, 1995.
PubMed
4) Edelstein CL:What is the role of tubular epithelial cell apoptosis in polycystic kidney disease (PKD) ? Cell Cycle 4:1548-1552, 2005.
 
5) Garner KD, Burnside JS, Elzinga LW, et al:Cytokines in fluids from polycystic kidney. Kidney Int 39:718-724, 1991.
 
6) Rankin CA, Suzuki K, Itoh Y, et al:Matrix metalloproteinases and TIMPs in cultured C57BL/6L-cpk kidney tubules. Kidnrey Int 50:835-844, 1996.
 
7) Nakamura T, Ushiyama C, Suzuki S, et al:Elavation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease. Am J Nephrol 20:32-36, 2000.
 
8) Ebihara I, Nakamura T, Ushiyama C, et al:Effect of oral adsorbent AST-120 on plasma MMP-9 and serum TIMP-1 concentrations in chronic renal failure. Nephron 83:169, 1999.
PubMed
9) Muzzillo DA, Imoto M, Fukuda Y, et al:Clinical evaluation of serum tissue inhibitor of metalloproteinase-1 levels in patients with liver diseases. J Gastroenterol Hepatol 8:437-441, 1993.
 
10) Eddy AA:Progression in chronic kidney disease. Adv Chronic Kidney Dis 12:353-365, 2005.
PubMed
11) Cowley BD Jr, Ricardo SD, Nagao S, et al:Increased renal expression of mocoyte chemoattractant protein-1 and osteopontin in ADPKD in rats. Kidney Int 60:2087-2096, 2001.
PubMed
12) Metcalf D, Mifsud S, Di Rago L, et al:Polycystic kidneys and chronic inflammatory lesions are the delayed consequences of loss of the suppressor of cytokine signaling-1 (SOCS-1). Proc Natl Acad Sci 99:943-948, 2002.
PubMed
13) Zheng D, Wolfe M, Cowley BD Jr, et al:Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 14:2588-2595, 2003.
PubMed
14) Lee JG, Ahn C, Yoon SC, et al:No association of the TGF-betal gene polymorphism with the renal progression in autosomal dominant polycystic kidney disease patients. Clin Nephrol 59:10-16, 2003.
 
15) Nakamura T, Ebihara I, Fukui M, et al:Effect of a specific ET receptor A antagonist on mRNA levels for ECM components and growth factors in diabetic glomeruli. Diabetes 44:895-899, 1995.
 
16) Nakamura T, Ebihara I, Tomino Y, et al:Effect of a specific ETa receptor antagonist onmurine lupus nephritis. Kidney Int 47:481-489, 1995.
 
17) Nakamura T, Ebihara I, Fukui M, et al:Increased endothelin and endothelin receptor mRNA expression in polycystic kidneys of cpk mice. J Am Soc Nephrol 4:1064-1072, 1993.
PubMed
18) Nakamura T, Ebihara I, Fukui M, et al:Modulation of endothelin family gene expression inrenal hypertrophy. Nephron 73:228-234, 1996.
 
19) Ebihara I, Nakamura T, Takahashi T, et al:Increased endothelin-1 mRNA expression in peripheral blood monocytes of dialysis patients. Peritoneal Dialysis Int 17:595-601, 1997.
PubMed
20) Taylor M, Johnson AM, Tison M, et al:Earlier diagnosis of autosomal dominant polycystickidney disease:Importance of family history and implications for cardiovascular and renal complications. Am J Kidney Dis 46:415-423, 2005.
 
21) Ong AC, Newby LJ, Dashwood MR:Expression and cellular localization of renal endothelin-1 and endothelin receptor subtypes in autosomal-dominant polycystic kidney disease. Nephron Exp Nephrol 93:e80, 2003.
PubMed
22) Al-nimri MA, Komers R, Oyama TT, et al:Endothelial-derived vasoactive mediators inpolycystic kidney disease. Kidney Int 63:1776-1784, 2003.
 
23) Merta M, Reiterova J, Rysava R, et al:Role of endothelin and nitric oxide in the pathogenesis of arterial hypertension in autosomal dominant polycystic kidney disease. Physiol Res 52:433-437, 2003.
PubMed
24) Maser RL, Vassmer D, Magenheimer BS, et al:Oxidant stress and reduced antioxidantenzyme protection in polycystic kidney disease. J Am Soc Nephrol 13:991-999, 2002.
 
25) Kamijo A, Sugaya T, Hikawa A, et al:Clinical evaluation of urinary excretion of livertype fatty acid-binding protein as a marker for the monitoring of chronic kidney disease:A multicenter trial. J Lab Clin Med 145:125-133, 2005.
PubMed
26) Nakamura T, Sugaya T, Kawagoe Y, et al:Effect of pitavastatin on urinary liver-type fattyacid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 28:2728-2732, 2005.
 
27) Nakamura T, Sugaya T, Kawagoe Y, et al:Candesartan reduces urinary fatty acid-bindingprotein excretion in patients with autosomal dominant polycystic kidney disease. Am J Med Sci 330:161-165, 2005.
 
28) Braun C, Kleemann T, Birck R, et al:Increased activity of the renal kallikrein-kininsystem in autosomal dominant polycystic kidney disease in rats, but not in humans. Int Immunopharmacol 2:1949-1956, 2002.
 
29) Braun C, Kleemann T, Hilgenfeldt U, et al:Activity and functional significance of the renal kallikrein-kinin system in polycystic kidney disease. Kidney Int 61:2149-2156, 2002.
PubMed
30) Rogers KK, Wilson PD, Snyder RW, et al:The exocyst localized to the primary cilium in MDCK cells. Biochem Biophys Res Commun 319:138-143, 2004.
 
31) Rogers KK, Jou TS, Guo W, et al:The Rho family of small GTPases is involved in epithelial cystogenesis and tubulogenesis. Kidney Int 63:1632-1634, 2003.
PubMed
P.145 掲載の参考文献
1) Dell KM, McDonald RA, Watkins SL, Avner ED:Polycystic kidney disease In Pediatric Nephrology. 5th ed, Avner ED, Harmon WE, Niaudet P (eds). p675-699, Lippincott Williams & Wilkins, Philadelphia, 2004.
 
2) Mucher G, Becker J, Knapp M, et al:Fine mapping of the autosomal recessive polycystic kidney disease locus (PKHD1) and the genes MUT, RDS, CSNK2 beta, and GSTA1 at 6p21. 1-p12. Genomics 48:40-45, 1998.
PubMed
3) Alvarez V, Malaga S, Navarro M, et al:Analysis of chromosome 6p in Spanish families with recessive polycystic kidney disease. Pediatr Nephrol 14:205-207, 2000.
PubMed
4) Ward CJ, Hogan MC, Rossetti S, et al:The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 30:259-269, 2002.
PubMed
5) Onuchic LF, Furu L, Nagasawa Y, et al:PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats. Am J Hum Genet 70:1305-1317, 2002.
PubMed
6) Zhang MZ, Mai W, Li C, et al:PKHD1 protein encoded by the gene for autosomal recessive polycystic kidney disease associates with basal bodies and primary cilia in renal epithelial cells. Proc Nat Acad Sci 101:2311-2316, 2004.
PubMed
7) Hiesberger T, Bai Y, Shao X, et al:Mutation of hepatocyte nuclear factor-1-beta inhibits Pkhd1 gene expression and produces renal cysts in mice. J CIin Invest l13:814-825, 2004.
 
8) Bergmann C, Senderek J, Kupper F, et al:PKHD1 mutations in autosomal recessive polycystic kidney disease (ARPKD). Hum Mutat 23:453-463, 2004.
PubMed
9) Bergmann C, Kupper F, Dornia C, et al:Algorithm for efficient PKHD1 mutation screening in autosomal recessive polycystic kidney disease (ARPKD). Hum Mutat 25:225-231, 2005.
PubMed
10) Zerres K, Mucher G, Becker J, et al:Prenatal diagnosis of autosomal recessive polycystic kidney disease (ARPKD):molecular genetics, clinical experience, and fetal morphology. Am J Med Genet 76:137-144, 1998.
PubMed
11) Zerres K, Senderek J, Rudnik-Schoneborn S, et al:New options for prenatal diagnosis in autosomal recessive polycystic kidney disease by mutation analysis of the PKHD1 gene. Clin Genet 66:53-57, 2004.
PubMed
12) Lager DJ, Qian Q, Bengal RJ, et al:The pck rat:a new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int 59:126-136, 2001.
 
13) Moser M, Matthiesen S, Kirfel J, et al:A mouse model for cystic biliary dysgenesis inautosomal recessive polycystic kidney disease (ARPKD). Hepatology 41:1113-1121, 2005.
PubMed
14) Katsuyama M, Masuyama T, Komura I, et al:Characterization of a novel polycystic kidney rat model with accompanying polycystic liver. Exp Anim 49:41-55, 2000.
 
15) Sanzen T, Harada K, Yasoshima M, et al:Polycystic kidney rat is a novel animal model of Caroli's disease associated with congenital hepatic fibrosis. Am J Pathol 158:1605-1612, 2001.
PubMed
16) Yoder BK, Hou X, Guay-Woodford LM:The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol 13:2508-2516, 2002.
 
17) Nakanishi K, Sweeney WE Jr, Zerres K, et al:Proximal tubular cysts in fetal humanautosomal recessive polycystic kidney disease. J Am Soc Nephrol 11:760-763, 2000.
PubMed
18) Guay-Woodford LM:Murine models of polycystic kidney disease:molecular and therapeutic insights. Am J Physiol Renal Physiol 285:F1034-1049, 2003.
PubMed
19) Hou X, Mrug M, Yoder BK, et al:Cystin, a novel cilia-associated protein, is disrupted in the cpk mouse model of polycystic kidney disease. J Clin Invest 109:533-540, 2002.
PubMed
20) Bissler JJ, Dixon BP:A mechanistic approach to inherited polycystic kidney disease. Pediatr Nephrol 20:558-66, 2005.
PubMed
21) Moyer JH, Lee-Tischler MJ, Kwon HY, et al:Candidate gene associated with a mutation causing recessive polycystic kidney disease in mice. Science 264:1329-1333, 1994.
PubMed
22) Nakanishi K, Sweeney WE Jr, Avner ED, et al:Expression of the orpk disease gene during kidney development and maturation. Pediatr Nephrol 16:219-226, 2001.
PubMed
23) Yoder BK, Richards WG, Sommardahl C, et al:Functional correction of renal defects in a mouse model for ARPKD through expression of the cloned wild-type Tg737 cDNA. Kidney Int 50:1240-1248, 1996.
 
24) Yoder BK, Richards WG, Sommardahl C, et al:Differential rescue of the renal and hepatic disease in an autosomal recessive polycystic kidney disease mouse mutant. A new model to study the liver lesion. Am J Pathol 150:2231-41, 1997.
 
25) Murcia NS, Richards WG, Yoder BK, et al:The Oak Ridge Polycystic Kidney (orpk) disease gene is required for left-right axis determination. Development 127:2347-2355, 2000.
PubMed
26) Mochizuki T, Saijoh Y, Tsuchiya K, et al:Cloning of inv, a gene that controls left/right asymmetry and kidney development. Nature 395:177-181, 1998.
PubMed
27) Otto EA, Schermer B, Obara T, et al:Mutations in INVS encoding inversin cause nephronophthisis type 2, linking renal cystic disease to the function of primary cilia and left-right axis determination. Nat Genet 34:413-420, 2003.
 
28) Yoder BK, Tousson A, Millican L, et al:Polaris, a protein disrupted in orpk mutant mice, is required for assembly of renal cilium. Am J Physiol Renal Physiol 282:F541-552, 2002.
PubMed
29) Nauta J, Ozawa Y, Sweeney WE Jr, et al:Renal and biliary abnormalities in a new murinemodel model of autosomal recessive polycystic kidney disease. Pediatr Nephrol 7:163-172, 1993.
 
30) Cogswell C, Price SJ, Hou X, et al:Positional cloning of jcpk/bpk locus of the mouse. Mamm Genome 14:242-249, 2003.
PubMed
31) Sweeney WE, Chen Y, Nakanishi K, et al:Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int 57:33-40, 2000.
PubMed
32) Sweeney WE Jr, Hamahira K, Sweeney J, et al:Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. Kidney Int 64:1310-1319, 2003.
PubMed
33) Sullivan LP, Wallace DP, Grantham JJ:Chloride and fluid secretion in polycystic kidney disease. J Am Soc Nephrol 9:903-916, 1998.
PubMed
34) Nakanishi K, Sweeney WE Jr, Macrae Dell K, et al:Role of CFTR in autosomal recessive polycystic kidney disease. J Am Soc Nephrol 12:719-25, 2001.
PubMed
35) Ward CJ, Yuan D, Masyuk TV, et al:Cellular and subcellular localization of the ARPKD protein ; fibrocystin is expressed on primary cilia. Hum Molec Genet 12:2703-2710, 2003.
PubMed
36) Nagano J, Kitamura K, Hujer KM, et al:Fibrocystin interacts with CAML, a protein involved in Ca2+ signaling. Biochem Biophys Res Commun 338:880-889, 2005.
PubMed

II 多発性嚢胞腎の臨床

P.151 掲載の参考文献
1) Gabow PA:Autosomal dominant polycystic kidney disease. N Engl J Med 329:332-342, 1993.
PubMed
2) Ravine D, Gibson RN, Walker RG, et al:Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 343:824-827, 1994.
PubMed
3) 進行性腎障害調査研究班(厚生労働省特定疾患進行性腎障害調査研究事業):多発性嚢胞腎診療指針. 厚生労働省, 東京, 2002. 151
 
P.153 掲載の参考文献
1) Johnson AM, Gabow PA:Identification of Patients with Autosomal Dominant Polycystic Kidney Disease at Highest Risk for End-Stage Renal Disease. J Am Soc Nephrol 8:1560-1567, 1997.
PubMed
2) Gabow PA, Duley I, Iohnson AM:Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease. Am J Kidney Dis 20:140-143, 1992.
PubMed
3) Chapman AB, Schrier RW:Pathogenesis of hypertension in autosomal dominant polycystic kidney disease. Semin Nephrol 11:653-660, 1991.
PubMed
4) Fick-Brosnahan GM, Belz MM, McFann KK, et al:Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease:A longitudinal study. Am J Kidney Dis 39:1127-1134, 2002.
PubMed
5) Gabow PA:Autosomal dominant polycystic kidney disease. N Engl J Med 329:332-342, 1993.
PubMed
6) Grantham JJ:The etiology, pathogenesis, and treatment of autosomal dominant polycystic kidney disease:Recent advances. Am J Kidney Dis 28:788-803, 1996.
PubMed
7) Dalgaard OZ:Bilateral polycystic disease of the kidneys. Acta Med Scand 328:1-255, 1957.
PubMed
8) King BF, Reed JE, Bergstralh EJ, et al:Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 11:1505-1511, 2000.
PubMed
9) Sise C, Kusaka M, Wetzel LH, et al:Volumetric determination of progression in autosomal dominant polycystic kidney disease by computed tomography. Kidney Int 58:2492-2501, 2000.
PubMed
10) Chapman AB, Guay-Woodford LM, Grantham JJ, et al:Renal structure in early autosomal, dominant polycystic kidney disease (ADPKD):The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 64:1035-1045, 2003.
 
11) Bae KT, Commean PK, Lee J:Volumetric measurement of renal cysts and parenchyma using MRI:Phantoms and patients with polycystic kidney disease. J Comput Assist Tomogr 24:614-619, 2000.
PubMed
12) Chapman AB:Cystic disease in women:Clinical characteristics and medical management. Adv Ren Replace Ther 10:24-30, 2003.
PubMed
13) Grantham JJ, Chapman AB, Torres VE:Volume Progression in Autosomal Dominant Polycystic Kidney Disease:The Major Factor Determining Clinical Outcomes. Clin J Am Soc Nephrol 1:148-157, 2006.
PubMed
P.157 掲載の参考文献
1) Watson ML:Hypertension in polycystic disease. In Polycystic Kidney Disease. Watoson ML, Torres VE (eds). chapt 16, p407-429, Oxford University Press, Oxford, 1996.
 
2) Wang D, Strandgaard S:The pathogenesis of hypertension in autosomal dominant polycystic kidney disease. J Hypertens 15:925-933, 1997.
PubMed
3) Ecder T, Schrier RW:Hypertension in autosomal-dominant polycystic kidney disease:Early occurrence and unique aspects. J Am Soc Nephrol 12:194-200, 2001.
PubMed
4) Hansson L, Kaarlander L-E, Lundgren W, et al:Hypertension in polycystic kidney disease. Scand J Urol Nephrol 8:203-205, 1974.
 
5) Gabow PA, Chapman AB, Johnson AM, et al:Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 38:1177-1180, 1990.
PubMed
6) Sedman A, Bell P, Manco-Johnson M, et al:Autosomal dominant polycystic kidney disease in childhood:A longitudinal study. Kidney Int 31:1000-1005, 1987.
PubMed
7) Fick GM, Johnson AM, Hammond WS, et al:Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5:2048-2056, 1995.
PubMed
8) Gabow PA, Johnson AM, Kaehny WD, et al:Factors sffecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 42:1311-1319, 1992.
 
9) Al-Nimuri MA, Komers R, Oyama TT, et al:Endothelial-derived vasoactive mediators in polycystic kidney disease. Kidney Int 63:1776-1784, 2003.
 
10) Wang D, Iversen J, Wilcox CS, et al:Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 64:1381-1388, 2003.
PubMed
11) Kim K, Drummond I, Ibraghimov-Beskrovnaya O, et al:Polycystine 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci USA 97:1731-1736, 2000.
 
12) Muto S, Aiba A, Saito Y, et al:Pioglitazone improves the phenotype and molecular defectsof a targeted Pkd1 mutant. Hum Mol Genet 11:1731-1742, 2002.
 
13) Gabow PA, Heard E, Pertorius D, et al:Relationship between renal structure and hypertension in autosomal dominant polycystic kidney disease (ADPKD). Kidney Int 31:297, 1987.
 
14) Nash MDAJ:Hypertension in polycystic kidney disease without renal failure. Arch Intern Me 137:1571-1575, 1977.
 
15) Valvo E, Gammaro L, Tessitore N, et al:Hypertension of polycystic kidney disease:Mechanisms and hemodynamic alterations. Am J Nephrol 5:176-181, 1985.
PubMed
16) Bell PE, Hossack KF, Gabow PA, et al:Hypertension in autosomal dominant polycystic kidney disease. Kidney Int 34:683-690, 1988.
PubMed
17) Chapman AB, Johnson A, Gabow PA, et al:The rennin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 323:1091-1096, 1990.
 
18) Harrap SB, Davies DL, Macnicol AM, et al:Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int 40:501-508, 1991.
PubMed
19) Wolf G, Neilson EG:Angiotensin II induces cellular hypertrophy in cultured murineproximal tubular cells. Am J Physiol 259:F768-777, 1990.
PubMed
20) Ruiz-Ortega M, Egido J:Angiotensin II modulates cell growth-related events and synthesisof matrix proteins in renal interstitial fibrosis. Kidney Int 52:1497-1510, 1997.
 
21) McPherson EA, Luo Z, Brown RA, et al:Chymase-like angiotensin II-generating activity inthe end-stage human autosomal dominant polycystic kidney disease. J Am Soc Nephrol 15:493-500, 2004.
 
22) Maschio G, Alberti D, Janin G, et al:Effect of angiotensin-converting-enzyme inhibitorbenazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939-945, 1996.
PubMed
23) Kanno Y, Suzuki H, Okada H, et al:Calcium channel blockers versus ACE inhibitors as antihypertensives in polycystic kidney disease. Q J Med 89:65-70, 1996.
 
24) Ecder T, Chapman AB, Brosnahan GM, et al:Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 35:427-432, 2000.
 
25) Ecder T, Edelstein CL, Chapman AB, et al:Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 14:1113-1116, 1999.
PubMed
26) van Dijk MA, Breuning MH, Duiser R, et al:No effect of enalapril on progression inautosomal dominant polycystic kidney disease. Nephrol Dial Transplant 18:2314-2320, 2003.
PubMed
27) Nutahara K, Higashihara E, Horie S, et al:Calcium channel blocker versus angiotensin II receptor blocker in autosomal polycystic kidney disease. Nephron Clin Pract 95:c18-c23, 2005.
 
28) Ecder T, Edelstein CL, Fick-Brosnahan, GM, et al:Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 21:98-103, 2001.
PubMed
29) Yamaguchi T, Nagao S, Wallace DP, et al:Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 63:1983-1994, 2003.
PubMed
30) Nagao S, Yamaguchi T, Kusaka M, et al:Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease. Kidney Int 63:427-437, 2003.
PubMed
31) Yamaguchi T, Wallace DP, Magenheimer BS, et al:Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 279:40419-40430, 2004.
 
P.167 掲載の参考文献
1) Arnaout MA:The vasculopathy of autosomal dominant polycystic kidney disease:insights from animal modals. Kidney Int 58:2599-2610, 2000.
 
2) Chauveau D, Sirieix ME, Schillinger F, et al:Recurrent rupture of intracranial aneurysms in autosomal dominant polycystic kidney disease. B M J 301:966-967, 1990.
 
3) Schievink WI, Torres VE, Wiebers DO, et al:Intracranial arterial dolichoectasia in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 8:1298-1303:1997.
 
4) Takagi H, Umemoto T:Abdominal aortic aneurysm and autosomal-dominant polycystic kidney disease. Letters to Editor. 376
 
5) Gibbs GF, Huston J III, Qian Q, et al:Follow-up of intracranial aneurysms in autosomal-dominant polycystic kidney disease. Kidney Int 65:1621-1627, 2004.
 
6) Chapman JR, Hilson AJW:Polycystic kidneys and abdominal aortic aneurysms. Lancet 315:646-647, 1980.
 
7) Leier CV, Baker PB, Kilman JW, et al:Cardiovascular abnormalities associated with adult polycystic kidney disease. Ann Intern Med 100:683-688, 1984.
PubMed
8) Pirson Y, Chauveau D, Grunfeld JP:Autosomal dominant polycystic kidney disease, in Oxford Textbook of Clinical Nephrology. Cameron S, Davison A, Grunfeld JP, et al (eds). p2393-2415, Oxford University Press, Oxford, 1997.
 
9) Hadimeri H, Norden G, Friman S, et al:Autosomal dominant polycystic kidney disease in a kidney transplant population. Nephrol Dial Transplant 12:1431-1436, 1997.
 
10) Gabow PA:Autosomal dominant polycystic kidoney disease. (review) N Engl J Med 329:332-342, 1993.
PubMed
11) SomLo S, Rutecki G, Giuffra LA, et al:A kinderd exhibiting cosegregation of an overlap connective tissue disorder and the chromosome 16 linked form of autosomal dominant polycystic kidney disease. J Am Soc Nephrol 4:1371-1378, 1993.
PubMed
12) Kulla L, Deymeer F, Smith TW, et al:Intracranial dissecting and saccular aneurysms in polycystic kidney disease. Arch Neurol 39:776-778, 1982.
PubMed
13) Paynter HE, Parnham A, Feest TG, et al:Thoracic aortic dissection complicating autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 12:1711-1713, 1997.
PubMed
14) Kanagasundaram NS, Perry EP, Turney JH:Aneurysm of the splenic artery in a patient with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 14:183-184, 1999.
 
15) Bobrie G, Brunet-Bourgin F, Alamowitch S, et al:Spntaneous artery dissection:Is it part of the spectrum of autosomal dominant polycystic kidney disease? Nephrol Dial Transplant 13:2138-2141, 1998.
 
16) Zeier M, Fehrenbach P, Geberth S, et al:Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 42:1259-1265, 1992.
PubMed
17) Graf S, Schischma A, Eberhardt KE, et al:Intracranial aneurysms and dolichoectasia in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 17:819-823, 2002.
PubMed
18) Qian Q, Li M, Cai Y, et al:Analysis of the polycystins in aortic vascular smooth muscle cells. J Am Soc Nephrol 14:2280-2287, 2003.
 
19) Chauvet V, Qian F, Boute N, et al:Expression of PKD1 and PKD2 transcripts and proteins in human embryo and during normal kidney development. Am J Patbology 160:973-983, 2002,
 
20) Torres VE, Cai Y, Chen X, et al:Vascular expression of polycystin-2. J Am Soc Nephrol 12:1-9, 2001.
 
21) Kim K, Drummond I, Ibraghimov-Beskrovnaya O, et al:Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci USA 97:1731-1736, 2000.
PubMed
22) Boulter C, Mulroy S, Webb S, et al:Cardiovascular, skeletal, and renal defects in mice with atargeted disruption of the Pkd1 gene. PNAS 98:12174-12179, 2001.
 
23) Muto S, Aiba A, Saito Y, et al:Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 11:1731-1742, 2002.
PubMed
24) Gao Z, Joseph E, Ruden DM, et al:Drosophila Pkd2 is haploid-insufficient for Mediating optimal smooth muscle contractility. J Biol Chem 279 (14):14225-14231, 2004.
PubMed
25) Kip SN, Hunter LW, Ren Q, et al:[Ca2+] I Reduction increases cellular proliferation and apoptosis in vascular smooth muscle cells. Relevance to the ADPKD phenotype. Circ Res 96:873-880, 2005.
 
26) Luscher TF, Boulangern CM, Dohi Y, et al:Endothelium-derived contracting factor. Hypertension 19:117-130, 1992.
 
27) Dohi Y, Criscioni L, Luscher TF:Renovascular hypertension impairs formation of endothelium-derived relaxing factors and sensitivity to endothelin-1 in small arteries. Br J Pharmacol 104:349-354, 1991.
 
28) Wang D, Iversen J, Strandgaard S:Contractility and endothelium-dependent relaxation of resistance vessels in polycystic kidney disease rats. J Vasc Res 36:502-509, 1999.
PubMed
29) Wang D, Iversen J, Strandgaard S:Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 11:1371-1376, 2000.
PubMed
30) Wang D, Iversen J, Wilcox CS, et al:Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosonal-dominant polycystic kidney disease. Kidney Int 64:1381-1388, 2003.
PubMed
31) Kocaman O, Oflaz H, Yekeler E, et al:Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 43 (5):854-860, 2004.
PubMed
32) Ramunni A, Saracino A, Esposito T, et al:Renal vascular resistance and Renin-Angiotensin system in the pathogenesis of early hypertension in autosomal dominant polycystic kidney disease. Hypertens Res 27 (4):221-225, 2004.
PubMed
33) Martinez-Vea A, Bardaji A, Gutierrez C, et al:Exercise blood pressure, cardiac structure, and diastolic function in young normotensive patients with polycystic kidney disease:A prehypertensive state. Am J Kidney Dis 44 (2):216-223, 2004.
 
34) Hadimeri H, Hadimeri U, Attman Per-Ola, et al:Dimensions of arteriovenous fistulas inpatients with autosomal dominant polycystic kidney disease. Nephron 85:50-53, 2000.
 
35) Weyde W, Krajewska M, Penar J, et al:Vascular abnormalities in patients with autosomaldominant polycystic kidney disease-the influence on arteriovenous fistula creation. Clinical Nephrology 61 (5):344-346, 2004.
 
36) Belz MM, Hughes RL, Kaehny WD, et al:Familial clustering of ruptured intracranial aneurysms in autosomal dominant polycystic kidney disease. Am J Kidney Dis 38:770-776, 2001.
PubMed
37) 東原英二:多発性嚢胞腎の治療. 臨床と研究76:1505-1511, 1999.
 
38) 東原英二:多発性嚢胞腎. 日本内科学会雑誌87:1298-1304, 1998.
 
39) Zeier M, Geberth S, Ritz E, et al:Adult dominant polycystic kidney disease-Clinical problems. Nephron 49:177-183, 1988.
PubMed
40) 円山英昭:目本病理剖検輯報による多嚢胞性疾患の統計的観察. 最新医学41:141-149, 1986.
 
41) Ryu SJ:Intracranial hemorrhage in patients with polycystic kidney disease. Stroke 21:291-294, 1990.
PubMed
42) Kushi H, Shibuya T, Tsubokawa T, et al:Intracranial hemomhage associated with polycysticliver and kidney disease-two case reports. Nihon Univ J Med 34:161-167, 1992.
 
43) 厚生労働省特定疾患対策研究事業 進行性腎障害調査研究 常染色体多発性嚢胞腎診療ガイドライン(第2版), 2006年.
 
44) 石倉宏恭, 谷口智行, 田中孝也, ほか: 多発性肝腎嚢胞症に合併した頭蓋内出血症例の検討. JJAAM 2:652-656, 1991.
 
45) 野口明男, 塩川芳昭, 齋藤勇:脳出血. 臨床と研究76:2357-2360, 1999.
 
46) Schievink WI, Torres VE, Piepgras DG, et al:Saccular intracranial aneurysms inautosomal dominant polycystic kidney disease. J Am Soc Nephrol 3:88-95, 1992.
PubMed
47) Suter W:Das kongenitale aneurysma der basalen gehirnarterien und cystennieren. Schweiz Med Wochenschr 79:471-476, 1949.
PubMed
48) Brown RAP:Polycystic disease of the kidneys and intracranial aneurysms. The etiology and interrelationship of these conditions. Review of the recent literature and report of seven cases in which both conditions coexisted. Glasgow Med J 32:333-348, 1951.
PubMed
49) Bigelow NH:The association of polycystic kidneys with intracranial aneurysms and otherrelated disorders. Am J Med Sci 225:485-494, 1953.
 
50) Chapman AB, Rubinstein D, Hughes R, et al:Intracranial aneurysms in autosomal dominantpolycystic kidney disease. N Engl J Med 327:916-920, 1992.
PubMed
51) Huston J, Torres VE, Sullivan PP, et al:Value of magnetic resonance angiography for the detection of intracranial aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 3:1871-1877, 1993.
 
52) Ruggieri PM, et al:Occult intracranial aneurysms in polycystic kidney disease:screening with MR angiography. Radiology 191:33-39, 1994.
PubMed
53) Atkinson JLD, Sundt TM Jr, Houser OW, et al:Angiographic frequency of anterior circulation interacranial aneurysms. J Neurosurg 70:551-555, 1989.
 
54) McCormick WF, Nofzinger JD:Saccular intracranial aneurysms:an autopsy study. J Neurosurg 22:155-159, 1965.
PubMed
55) Inagawa T, Hirano A:Autopsy study of unruptured incidental intracranial aneurysms. Surg Neurol 34:361-365, 1990.
PubMed
56) Pirson Y, Chauveau D:Cerebral aneurysms, in Watson M, Torres V (eds) ; Polycystic kidney disease. p205-227, Oxford University press, Oxford, England, 1996.
 
57) Mariani L, Bianchetti MG, Schroth G, et al:Cerebral aneurysms in patients with autosomal dominant polycystic kidney disease-to screen, to clip, to coil? Nephrol Dial Transplant 14:2319-2322, 1999.
PubMed
58) Chauveau D, Pirson Y, Verellen-Dumoulin C, et al:Intracranial aneurysms in autosomal dominant polycystic kidney disease. Kidney Int 45:1140-1146, 1994.
PubMed
59) Lozano AM, Leblanc R:Cerebral aneurysms and polycystic kidney disease:A critical review. The Canadian J Neurological Sciences 19:222-227, 1992.
 
60) Kassell NF, Torner JC, Haley EC, et al:The international cooperative study on the timing of aneurysm surgery. Part 1 ; Overall management results. J Neurosurg 73:18-36, 1990.
 
61) Locksley HB:Report on the cooperative study of intracranial aneurysms and subarachnoid hemorrhage. Section V, part I. Natural history of subarachnoid hemorrhage, intracranial aneurysms and arteriovenous malformations. Based on 6368 cases in the cooperative study. J Neurosurg 25:219-239, 1967.
 
62) Lilova MI, Petkov DL:Intracranial aneurysms in a child with autosomal recessive polycystic kidney disease. Pediatr Nephrol 16:1030-1032, 2001.
 
63) Gieteling EW, Rinkel GJ:Characteristics of intracranial aneurysms and subarachnoid haemorrhage in patients with polycystic kidney disease. J Neurol 250:418-423, 2003.
PubMed
64) Wang PS, Longstreth WT, Koepsell TD:Subarachnoid hemorrhage and family history:A population-based case control study. Arch Neurol 52:202-204, 1995.
PubMed
65) Bromberg JEC, Rinkel GJE, Algra A, et al:Subarachnoid in first and second degree relatives of patients with subarachnoid haemorrhage. BMJ 311:288-289, 1995.
 
66) Schievink WI, Schaid DJ, Michels VV, et al:Familial aneurismal subarachnoid hemorrhage:A community-based study. J Neurosurg 83:426-429, 1995.
 
67) Nakajima F, Shibahara N, Arai M, et al:Ruptured cerebral aneurysm not detected by magnetic resonance angiography in juvenile autosomal dominant polycystic kidney. Int J Urol 7:153-156, 2000.
 
68) Schievink WI, Prendergast V, Zabramski JM:Rupture of a previously documented small asymptomatic intracranial aneurysm in a patient with autosomal dominant polycystic kidney disease. J Neurosurg 89:479-482, 1998.
 
69) Wiebers DO, Whisnant JP, Sundt TM, et al:The significance of unruptured intracranial saccular aneurysms. J Neurosurg 66:23-29, 1987.
PubMed
70) Wiebers DO, Whisnant JP, O'Fallon WM:The natural history of unruptured intracranial aneurysms. N Engl J Med 304:696-698, 1981.
PubMed
71) Levey AS:Cerebral aneurysms. In:Grantham JJ, Gardner KD (eds). Problems in diagnosis and management of polycystic kidney disease. p135-144, PKR Foundation, Kansas City, 1985.
 
72) Locksley HB:Report on the cooperative study of intracranial aneurysms and subarachnoid hemorrhage. Section V, part I. Natural history of subarachnoid hemorrhage, intracranial aneurysms and arteriovenous malformations. Based on 6368 cases in the cooperative study. J Neurosurg 25:219-239, 1967.
 
73) Dalgaard OZ:Bilateral polycystic disease of the kidneys:A follow-up of two hundred and eighty-four patients and their families. Acta Med Scand 328:S1-S255, 1957. (supp1 1)
 
74) Iglesias CG, Torres VE, Offord KP, et al:Epidemiology of adult polycystic kidney disease. Am J Kidney Dis 2:630-639, 1983.
PubMed
75) Watson ML:Complications of polycystic kidney disease. Kidney Int 51:353-365, 1997.
PubMed
76) Levey AS, Pauker SG, Kassirer JP:Occult intracranial aneurysms in polycystic kidneydisease:When is cerebral arteriography indicated? NEngl J Med 308:986-994, 1983.
 
77) Levey AS:Screening for occult intracranial aneurysms in polycystic kidney disease:Interim guidelines. J Am Soc Nephrol 1:9-12, 1990.
PubMed
78) Butler WE, Barker FG, Crowell RM:Patients with polycystic kidney disease would benefitfrom routine magnetic resonance angiographic screening for intracerebral aneurysms:A decision analysis. Neurosurgery 38:506-515, 1996.
 
79) Huston J, Torres VE, Wiebers DO:Follow-up of intracranial aneurysms in autosomal dominant polycystic kidney disease by magnetic resonance angiography. J Am Soc Nephrol 7:2135-2141, 1996.
PubMed
80) Lever AS, Pauker SG, Kassirer JP:Occult intracranial aneurysms in polycystic kidney disease:When is cerebral arteriography in dicated? N Engl Med 308:986. 994, 1983.
 
81) Vega C, Kwoon J, Lavine S, et al:Intracranial aneurysms:Current evidence and clinical practice. Am Family Physician 66:601-608, 2002.
PubMed
82) Leipziger J:Control of epithelial transport via luminal P2 receptors. Am J physiol Renal physiol 284:F419-F432, 2003.
PubMed
83) Eelco FM, Wijdicks MD, Vicente E, et al:Chronic subdural hematoma in autosomal dominant polycystic kidney disease. Am J Kidney Dis 35:40-43, 2000.
 
84) Slaba SG, El-Hajj LF, Abboud GA, et al:Selective angiography of cerebral aneurysm using gadodiamide in polycystic kidney disease with renal insufficiency. AJR 175:1467-1468, 2000.
PubMed
85) Nakajima F, Shibuhara N, Arai M, et al:Intracranial aneurysms and autosomal dominantpolycystic kidney disease:Followup study by magnetic resonance angiography. J Urology 164:311-313, 2000.
 
86) Leung GKK, Fan YW:Chronic subdural haematoma and arachnoid cyst in autosomaldominant polycystic kidney disease (ADPKD). Journal of Clinical Neuroscience 12 (7):817-819, 2005.
 
P.174 掲載の参考文献
1) 日本脳ドック学会「脳ドックあり方委員会」, 1997 (平成9) 年5月.
 
2) The International Study of Unruptured Intracranial Aneurysms Investigators:Unruptured intracranial aneurysms-Risk of rupture and risks of surgical intervention. N Engl J Med 339:1725-1733, 1998
 
3) The International Study of Unruptured Intracranial Aneurysms Investigators:Unruptured intracranial aneurysms:natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 362 (9378):103-10, 2003.
 
4) 日本未破裂脳動脈瘤悉皆調査(UCAS Japan)中間報告. 第61回日本脳卒中の外科学会, 平成16年3月19日. 名古屋およびUCAS Japanホームページ http://ucas-j. umin. ac. jp/home. htm
 
5) 日本脳ドック学会「脳ドックの新ガイドライン作成委員会 2003 (平成15) 年9月.
 
6) 科学的根拠に基づくくも膜「出血診療ガイドライン(2001), 平成13年度研究報告書.
 
7) 脳卒中合同ガイドライン委員会:脳卒中治療ガイドライン2004, 協和企画, 2004.
 
8) International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms:arandomised trial. Lancet 360:1267-74, 2002.
PubMed
9) ランセットISAT論文に関する新聞報道等に対する見解. 日本脳神経外科学会ホームページ http://jns. umin. ac. jp
 
P.185 掲載の参考文献
1) Ubara Y, Katori H, Tagami T, et al:Transcatheter renal arterial enbolization therapy on a patient with polycystic kidney disease on hemodialysis. Am J Kidney Dis 34:926-931, 1999.
 
2) Ubara Y, Tagami T, Sawa N, et al:Renal contraction therapy for enlarged polycystic kidneys by transcatheter arterial embolization in hemodialysis patients. Am J Kidney Dis 39:571-579, 2002.
PubMed
3) Harley JD, Shen FH, Carter SJ:Transcatheter infarction of a polycystic kidney for control of recurrent hemorrhage. Am J Roentogenology 134:818-820, 1980.
 
4) Bello-Reuss E, Holubec K, Rajaraman S:Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int 60:37-45, 2001.
PubMed
5) 香村衡一: 特集ガイドラインに基づく腎尿路疾患診療-診断・予防・治療, [泌尿器疾患]多発性嚢胞腎. 腎と透析 56:763-768, 2004.
 
6) Torres VE:Extrarenal manifestations of autosomal dominant polycystic kidney disease. Am J Kidney Dis:xlv-xlviii, 1999.
PubMed
7) Elzinga LW, Barry JM, Torres VE, et al:Cyst decompression surgery for autosomal dominant polycystic kidney disease. J Am Soc Nephrol:1219-1226, 1992.
PubMed
8) 福岡洋, 石橋克夫, 藤波潔, ほか:血液透析中の嚢胞腎の腎摘除術. 泌尿器外科 7:43-46, 1994.
 
9) Bendavid Y, Moloo H, Klein L, et al:Laparoscopic nephrectomy for autosomal dominant polycystic kidney disease. Surg Endosc 18:751-754, 2004.
PubMed
10) 酒井敬介:肝嚢胞(非寄生虫性肝嚢胞) . 消化器疾患最新の治療2001-2002 (戸田剛太郎, 杉町圭蔵, 中村孝司編), p333-335, 南江堂, 2002.
 
11) Takegoshi K, Tanaka K, Nomura H, et al:Successful living donor liver transplantation for polycystic liver in a patient with autosomal-dominant polycystic kidney disease. J CIin Gastroenterol 33:229-231, 2001.
 
12) Ubara Y, Takei R, Hoshino J, et al:Intravascular embolization therapy in a patient with an enlarged polycystic liver. Am J Kidney Dis 43:733-738, 2004.
 
13) Ubara Y, Higa Y, Tagami T, et al:Pelvic insufficiency fracture related to autosomal dominant polycystic kidney disease. Am J Kidney Dis 46 (6):e103-11, 2005.
PubMed
P.186 掲載の参考文献
1) Kim K, Drummond I, Ibraghimov-Beskrovnaya O, et al:Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci USA 97:1731-1736, 2000.
PubMed
2) Torres VE:Extrarenal manifestations of autosomal dominant polycystic kidney disease. Am JKidney Dis 34:xlv-xlviii, 1999.
PubMed
3) Hadimeri H, Lamm C, Nyberg G:Coronary aneurysms in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 9:837-841, 1998.
PubMed
4) Hossak KF, Leddy CL, Johnson AM, et al:Echocardiographic findings in autosomal dominant polycystic kidney disease. N Engl J Med 319:907-912, 1988.
 
5) Ivy D, Shaffer EM, Johnson AM, et al:Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5:2032-2036, 1995.
PubMed
6) 河邊香月, 東原英二, 堀江重郎: 多発性嚢胞腎分科会報告. 厚生省特定疾患進行性腎障害調査研究班 平成五年度研究業績報告書. 黒川清班, p183-196, 厚生省, 1994.
 
7) Martinez JR, Grantham JJ:Polycystic kidney disease:etiology, pathogenesis, and treatment. Dis Mon 41:693-765, 1995.
PubMed
8) Zeier M, Geberth S, Schmidt KG, et al:Elevated blood pressure profile and left ventricular mass in children and young adults with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 3:1451-1457, 1993.
 
9) Martinez-Vea A, Bardaji A, Gutierrez C, et al:Echocardiographic evaluation in patients with autosomal dominant polycystic kidney disease and end-stage renal disease. Am J Kidney Dis 34:264-272, 1999.
PubMed
P.189 掲載の参考文献
1) Gabow PA, Johnson AM, Kaehny WD, et al:Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 41:1311-1319, 1992.
PubMed
2) Telenti A, Torres VE, Gross JB Jr, et al:Hepatic cyst infection in autosomal dominant polycystic kidney disease. Mayo Clin Proc 65:933-942, 1990.
PubMed
3) Fick GM, Johnson AM, Hammond WS, et al:Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5:2048-2056, 1995.
PubMed
4) 日本透析医学会統計調査委員会:わが国の慢性透析療法の現況(2004年12月31日現在) . (社)日本透析医学会統計調査委員会, 東京, 2005.
 
5) Martinez JR, Grantham JJ:Polycystic kidney disease:etiology, pathogenesis, and treatment. Dis Mon 41:693-765, 1995.
PubMed
6) 香村衡一:特集-透析と嚢胞性腎疾患-I常染色体優性多発性嚢胞腎 (2) 臨床症状・診断・合併症. 臨床透析 18:512-524, 2002.
 
7) Bleeker-Rovers CP, de Sevaux RG, van Hamersvelt HW, et al:Diagnosis of renal and hepatic cyst infections by 18-F-fluorodeoxyglucose positron emission tomography in autosomal dominant polycystic kidney disease. Am J Kidney Dis 41:E18-21, 2003.
PubMed
8) Elzinga LW, Bennett WM:Miscellaneous renal and systemic complications of autosomal dominant polycystic kidney disease including infection. In:Polycystic Kidney Disease. Watson ML, Torres VE (eds). p483-499, Oxford University Press, Oxford, 1996.
 
P.191 掲載の参考文献
1) Higashihara E, Aso Y, Shimazaki J, et al:Clinical aspects of polycystic kidney disease. J Urol 147:329-332, 1992.
PubMed
2) Torres VE, Erickson SB, Smith LH, et al:The association of nephrolithiasis and autosomal dominant polycystic kidney disease. Am J Kidney Dis 11:318-325, 1988.
PubMed
3) Levine E, Grantham JJ:Calcified renal stones and cyst calcifications in autosomal dominant polycystic kidney disease:clinical and CT study in 84 patients. AJR 159:77-81, 1992.
PubMed
4) Terai A, Toshida O:Epidemiology of urolithiasis in Japan. In:Recent Advances in treatment of Urolithiasis. Recent Advances in Endourology Vol 3, Akimoto M, Higashihara E, Orikasa S, et al (eds). p23-36, Spronger-Verlag, Tokyo, 2001.
 
5) Grampsas SA, Chandhoke PS, Fan J, et al:Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 36:53-57, 2000.
PubMed
6) Torres VE, Wilson DM, Hattery RR, et al:Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis 22:513-519, 1993.
PubMed
7) Torres VE, Keith DS, Pfford KP, et al:Renal ammonia in autosomal dominant polycystic kidney disease. Kidney Int 45:1745-1753, 1994.
 
P.194 掲載の参考文献
1) Higashihara E, Aso Y, Shimazaki J, et al:Clinical aspects of polycystic kidney disease. J Urol 147:329-332, 1992.
PubMed
2) Segura JW, King BF, Jowsey SG, et al:Chronic pain and its medical and surgical management in renal cystic disease. In Polycystic Kidney Disease. Watoson ML, Torres VE (eds). chapt 19, p462-480, Oxford University Press, Oxford, 1996.
 
3) Bajwaq ZH, Sial KA, Malik AB, et al:Pain patterns in patients with polycystic kidney disease. Kidney Int 66:1561-1569, 2004.
 
4) Bajwaq ZH, Gupta A, Warfield CA, et al:Pain management in polycystic kidney disease. Kidney Int 60:1631-1644, 2001.
 
5) Ubara Y, Katori H, Tagami T, et al:Transcatheter renal arterial embolization therapy on a patient with polycystic kidney disease. Am J Kidney Dis 34:926-931, 1999.
PubMed
P.198 掲載の参考文献
1) Torra R, Nicolau C, Badenas C, et al:Ultrasonographic study of pancreatic cysts in autosomal dominant polycystic kidney disease. Clin Nephrol 47:19-22, 1997.
 
2) Malka D, Hammel P, Vilgrain V, et al:Chronic obstructive pancreatitis due to a pancreatic cyst in a patient with autosomal dominant polycystic kidney disease. Gut 42:131-134, 1998.
 
3) Michels V:Von Hippel-Lindau disease. In:Polycystic Kidney Disease. Watson ML, Torres VE (eds). p309-330, 0xford University Press, Oxford, 1996.
 
4) Ishikawa I, Chikamoto E, Nakamura M, et al:High incidence of common bile duct dilatation in autosomal dominant polycystic kidney disease patients. Am J Kidney Dis 27:321-326, 1996.
PubMed
5) Gabow PA:Autosomal dominant polycystic kidney disease. N Engl J Med 329:332-342, 1993.
PubMed
6) Martinez JR, Grantham JJ:Polycystic kidney disease:etiology, pathogenesis, and treatment. Dis Mon 41:693-765, 1995.
PubMed
7) Schievink WI, Huston J III, Torres VE, et al:Intracranial cysts in autosomal dominant polycystic kidney disease. J Neurosurg 83:1004-1007, 1995.
 
8) Schievink WI, Torres VE:Spinal meningeal diverticula in autosomal dominant polycystic kidney disease. Lancet 349:1223-1224, 1997.
PubMed
9) Stamm ER, Townsend RR, Johnson AM, et al:Frequency of ovarian cysts in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 34:120-124, 1999.
PubMed
10) Belet U, Danaci M, Sarikaya S, et al:Prevalence of epididymal, seminal vesicle, prostate, and testicular cysts in autosomal dominant polycystic kidney disease. Urology 60:138-141, 2002.
PubMed
11) Danaci M, Akpolat T, Bastemir M, et al:The prevalence of seminal vesicle cysts in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 13:2825-2828, 1998.
PubMed
12) Okada H, Fujioka H, Tatsumi N, et al:Assisted reproduction for infertile patients with 9+0 immotile spermatozoa associated with autosomal dominant polycystic kidney disease. Hum Reprod 14:110-113, 1999. Erratum in:Hum Reprod 14:1166, 1999.
 
13) Sharp CK, Zeligman BE, Johnson AM, et al:Evaluatiion of colonic diverticular disease in autosomal dominant polycystic kidney disease without end-stage renal disease. Am J Kidney Dis 34:863-868, 1999.
 
14) Lederman ED, McCoy G, Conti DJ, et al:Diverticulitis and polycystic kidney disease. Am Surg 66:200-203, 2000.
PubMed
15) Pena JM, Pernaute R, Vicente de Vera C:Is ADPKD associated with small-bowel diverticular disease? Nephrol Dial Transplant 15:1890-1891, 2000.
PubMed
16) Elzinga LW, Bennett WM:Miscellaneous renal and systemic complications of autosomal dominant polycystic kidney disease including infection. In:Polycystic Kidney Disease. Watson ML, Torres VE (eds). p309483-499, Oxford University Press, Oxford, 1996.
 
17) Rosse WF, Waldmann TA, Cohen P:Renal cysts erythropoietin, and polycythemia. American Journal of Medicine 34:76-81, 1963.
PubMed
18) Abbott KC, Agodoa LY:Polycystic kidney disease at end-stage renal disease in the United States:patient characteristics and survival. Clinical Nephrology 57:208-214, 2002.
PubMed
19) 吉田泉, 武田茂幸, 宮田幸雄, ほか:透析導入となった多発性嚢胞腎 (PCK) の臨床的検討. 透析会誌 28:1353-1358, 1995.
 
20) Trimble M, Caro J, Talalla A, et al:Secondary erythrocytosis due to a cerebellar hemangioblastoma:demonstration of erythropoietin mRNA in the tumor. Blood 78:599-601, 1991.
PubMed
21) 大井景子, 山本裕泰, 重松隆, ほか:腎細胞癌の腫瘍マーカーとして血中エリスロポエチン濃度が有用であった血液透析患者の1例. 透析会誌 30:141-145, 1997.
 
22) Banerjee A, Chandna S, Jayasena, et al:Leucopenia in adult polycystic kidney disease patients on haemodialysis. Nephron 91:175-176, 2002.
PubMed
23) Merta M, Tesar V, Zima T, et al:Cytokine profile in autosomal dominant polycystic kidney disease. Biochem Mol Biol Int 41:619-624, 1997.
PubMed
24) O'Sullivan DA, Torres VE, Heit JA, et al:Compression of the inferior vena cava by right renal cysts:an unusual cause of IVC and/or iliofemoral thrombosis with pulmonary embolism in autosomal dominant polycystic kidney disease. Clin Nephrol 49:332-334, 1998.
PubMed
25) Cannon TW, Norris JP:Right atrial embolus after percutaneous decompression of obstructing cysts in autosomal dominant polycystic kidney disease. J Urol 163:542-543, 2000.
PubMed
26) Slegtenhorst Mv, Hoogt Rd, Hermans C, et al:Identification of the tuberous sclerosis gene TSCI on chromosome 9q34. Science 277:805-808, 1997.
 
27) The European Chromosome 16 Tuberous Sclerosis Consortium:Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75:1305-1315, 1993.
PubMed
28) Martignoni G, Bonetti F, Pea M, et al:Renal disease in adults with TSC2/PKD1 contiguous gene. Am J Surg Pathol 26:198-205, 2002.
PubMed
29) Brook-Carter PT, Peral B, Ward CJ, et al:Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease:a contiguous gene syndrome. Nat Genet 8:328-332, 1994.
PubMed
30) Sampson JR, Maheshwar MM, Aspinwall R, et al:Renal cystic disease in tuberous sclerosis:role of the polycystic kidney disease l gene. Am J Hum Genet 61:843-851, 1997.
 
31) Ong A, Harris P, Davies D, et al:Polycystin-1 expression in PKD1, early-onset PKD1, and TSC2/PKD1 cystic tissue. Kidney Int 56:1324-1333, 1999.
PubMed
32) Kleymenova E, Ibraghimov-Beskrovnaya O, Kugoh H, et al:Tuberin-Dependent membrane localization of polycystin-1:A functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Moleculer Cell 7:823-832, 2001.
 
33) Chen YL, Luo CB, Hsu SW, et al:Tuberous sclerosis complex with an unruptured intracranial aneurysm:manifestations of contiguous gene syndrome. Int Neuroradiology 7:337-341, 2001.
 
34) Brum FA, Becker M, Uglione A, et al:Polycystic horseshoe kidney. J Urol 158:2229, 1997.
PubMed
35) Caglar K, Kibar Y, Tahmaz L, et al:Polycystic horseshoe kidney. Clinical Nephrology 55:487-488, 2001.
PubMed
36) Strassburg A, Schirg E, Ehrich JHH:A child with polycystic kidney disease:do we have to care about associated malformations? Nephrol Dial Transplant 16:1942-1944, 2001.
 
37) Cefle K, Yildiz A, Palanduz S, et al:Chronic renal failure in a patient with sotos syndrome due to autosomal dominant polycystic kidney disease. IJCP 56:316-318, 2002.
 
38) Hateboer N, Buchalter M, Davies SJ, et al:Co-Occurrence of autosomal dominant polycystic kidney disease and marfan syndrome in a kindred. Am J Kidney Dis 35:753-760, 2000.
 
39) Grubb III RB, Collyer WC, Kibel AS:Transitional cell carcinoma of the renal pelvis associated with hypercalcemia in a patient with autosomal dominant polycystic kidney disease. Urology 63 (4):778. e4-778. e6, 2004.
 
40) Lang EK, Davis R:Autosomal dominant polycystic disease with renal cell carcinoma. J Urology 173:987, 2005.
 
41) Hama Y, Kaji T, Hayakawa M, et al:Erythropoietin-producing renal cell carcinoma arising from autosomal dominant polycystic kidney disease. The British Journal of Radiology 78:269-271, 2005.
PubMed
42) Niemann U, Behrend M:Bilateral endoscopic adrenalectomy for cushing, s syndrome in a patient with polycystic liver and kidney disease. Surg Laoarosc Endosc Percutan Tech 14(1):35-37, 2004.
 
43) Minardi D, Mantovani P, Dellabella M, et al:Renal sarcoma associated with adult polycystic kidney disease. A case report and literature review. Arch ital Urol Androl 76 (2):94-96, 2004.
PubMed
44) Nishida T, Ishihara S, Kaji T, et al:Polycystic kidney disease associated with cervical arteriovenous shunt and bilateral jugular vein occlusion. Intenal Medicine 41 (11):1036-1038, 2002.
 
45) Shibata R, Okita H, Shimoda M, et al:Primary carcinoid tumor in a polycystic kidney. Pathology International 53:317-322, 2003.
 
46) Chen MH, Chen KS, Hou JW, et al:Coexistence of autosomal dominant polycystic kidney disease and neurofibromatosis:Report of a family. Am J Nephrol 22:376-380, 2002.
PubMed
47) Flego V, Badocinac AR, Plese V, et al:Malignancy risk in patient with Neurofibromatosis and autosomal dominant polycystic kidney disesase. Croat Med J 44:485-488, 2003.
 
48) Colloby PS, Newman J, Tudway D:Multiple congenital abnormalities in association with adult polycystic renal disease. Histopathology 16:607-608, 1990.
PubMed
49) Abreo K, Steele TH:Simultaneous medullary sponge and adult polycystic kidney disease. The Need for accurate diagnosis. Arch Inten Med 142:163-165, 1982.
 
P.205 掲載の参考文献
1) 常染色体劣性遺伝多発性嚢胞腎. 腎臓病学の診断アプローチ. p92, 社団法人日本腎臓学会, 1995.
 
2) Zerres K, Mucher G, Becker J, et al:Prenatal diagnosis of autosomal recessive polycystic kidney disease (ARPKD):molecular genetics, clinical experience, and fetal morphology. Am J Med Genet 76:137-144, 1998.
PubMed
3) Dell KM, McDonald RA, Watkins SL, Avner ED:Polycystic kidney disease In Pediatric Nephrology. 5th ed, Avner ED, Harmon WE, Niaudet P (eds). p675-699, Lippincott Williams & Wilkins, Philadelphia, 2004.
 
4) Zerres K, Senderek J, Rudnik-Schoneborn S, et al:New options for prenatal diagnosis in autosomal recessive polycystic kidney disease by mutation analysis of the PKHD1 gene. Clin Genet 66:53-57, 2004.
PubMed
5) Garel L:Sonography of renal cystic disease and dysplasia in infants and children In:Pediatric Nephrology. Brodehl J, Ehrich JHH (eds). p359-362, Springer, Berlin, 1998.
 
6) Jung G, Benz-Bohm G, Kugel H, et al:MR cholangiography in children with autosomal recessive polycystic kidney disease. Pediatr Radiol 29:463-466, 1999.
PubMed
7) Kern S, Zimmerhackl LB, Hildebrandt F, et al:Appearance of autosomal recessive polycystic kidney disease in magnetic resonance imaging and RARE-MR-urography. Pediatr Radiol 30:156-60, 2000.
PubMed
8) Guay-Woodford LM, Desmond RA:Autosomal recessive polycystic kidney disease:the clinical experience in North America. Pediatrics 111:1072-80, 2003.
PubMed
9) Capisonda R, Phan V, Traubuci J, et al:Autosomal recessive polycystic kidney disease:clinical course and outcome, a single center experience. Pediatr Nephrol 18:119-126, 2003.
PubMed
10) Zerres K, Rudnik-Schoneborn S, Deget F, et al:Autosomal recessive polycystic kidney disease in 115 children:clinical presentation, course and influence of gender. Acta Paediatr 85:437-445, 1996.
PubMed
11) Kaariainen H, Jaaskelainen J, Kivisaari L, et al:Dominant and recessive polycystic kidney disease in children:classification by intravenous pyelography, ultrasound, and computed tomography. Pediatr Radiol 18:45-50, 1998.
 
12) Gagnadoux MF, Habib R, Levy M, et al:Cystic renal diseases in children. Adv Nephrol Necker Hosp 18:33-57, 1989.
PubMed
13) Roy S, Dillon MJ, Trompeter RS, et al:Autosomal recessive polycystic kidney disease:long-term outcome of neonatal survivors. Pediatr Nephrol 11:302-306, 1997.
PubMed
14) Munding M, Al-Uzri A, Gralnek D, et al:Prenatally diagnosed autosomal recessive polycystic kidney disease:initial postnatal management. Urology 54:1097, 1999.
 
15) Jamil B, McMahon LP, Savige JA, et al:A study of long-term morbidity associated with autosomal recessive polycystic kidney disease. Nephrol Dial Transplant 14:205-9, 1999.
PubMed

III 多発性嚢胞腎の治療

P.217 掲載の参考文献
1) Ohnishi A, Orita Y, Takagi N, et al:Aquaretic effect of a potent, orally active, Nonpeptide V2 antagonist in men. J Pharmacol Exp Ther 272:546-551, 1995.
 
2) Gattone VH, Wang X, Harris PC, et al:Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9:1323-1326, 2003.
PubMed
3) Gattone VH 2"d, Wang X, Harris PC, et al:Do vasopressin receptor type 2 antagonists have therapeutic potential in polycystic kidney diseases? Expert Opin Investig Drugs 13:431-434, 2004.
 
4) Torres VE, Wang X, Qian Q, et al:Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med doi:10. 1038/nm1004, February, 2004.
 
5) Wang X, Gattone II V, Harris PC, et al:Effectiveness of vasopression V2 receptor antagonists OPC-31260 and OPC-410610n polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16:846-851, 2005.
 
6) Grantham JJ:Understanding polycystic kidney disease:A systems biology approach. Kidney Int 64:1157-1162, 2003.
PubMed
7) Torres VE:Therapies to slow polycystic kidney. Nephron Exp Nephrol 98:e1-e7, 2004.
PubMed
8) Schultz BD, DeRoos ADG, Venglarik CJ, et al:Glibenclamide blockade of CFTR chloride channels. The American Physiological society. L192-L200, 1996.
 
9) Zhang Z-R, Zeltwanger S, McCarty NA:Steady-State interactions of glibenclamide with CFTR:Evidence for multiple sites in the pore. J Membrane Biol 199:15-28, 2004.
 
10) Sullivan LP, Wallace DP, Gover T, et al:Sulfonylurea-Sensitive K+ transport is involved in Cl-secretion and cyst growth by cultured ADPKD cells. J Am Soc Nephrol 13:2619-2627, 2002.
 
11) Scott-Ward ST, Li H, Schmidt A, et al:Direct block of the cystic fibrosis transmembrane conductance regulator Cl-channel by niflumic acid. Mol Memb Biol 21:27-38, 2004.
 
12) Fuller MD, Zhang Z, Cui G, et al:Inhibition of CFTR channels by a peptide toxin of scorpion venom. Am J Phtsiol Cell physiol 287:1328-1341, 2004.
 
13) Li H, Findlay I, Sheppard D:The relationship between cell proliferation, Cl-secretion, and renal cyst growth:A study using CFTR inhibitors. Kidney Int 66:1926-1938, 2004.
PubMed
14) Lu J, Bankovic-Calic N, Ogborn M, et al:Detrimental effects of a high fat diet in early renal injury are ameliorated by fish oil in han:SPRD-cy Rats1. 2. J Nutr 133:180-186, 2003.
 
15) Jayapalan S, Saboorian MH, Edmunds JW, et al:High dietary fat intake increases renal cyst disease progression in han:SPRD-cy Rats. Am Soc Nutritional Sciences 130:2356-2360, 2000.
 
16) Ogborn MR, Nitschmann E, Weiler HA, et al:Modification of polycystic kidney disease and fatty acid status by soy protein diet. Kidney Int 57:159-166, 2000.
PubMed
17) Aukema H, Housini I, Rawling J:Dietary soy protein effects on disease and IGF-I in male and female Han:SPRD-cy rats. Kidney Int 59:52-61, 2001.
 
18) Gabow PA, Chapman AB, Johnson AM, et al:Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 38:1177-1180, 1990.
PubMed
19) Nagao S, Yamaguchi T, Kasahara M, et al:Effect of probucol in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 35:221-226, 2000.
 
20) Philbrick DJ, Bureau DP, Collins FW, et al:Evidence that soyasaponin Bb retards disease progression in a murine model of polycystic kidney disease. Kidney Int 63:1230-1239, 2003.
 
21) Aukema H, Yamaguchi T, Takahashi H, et al:Effects of dietary fish oil on survival and renal fatty acid composition in murine polycystic kidney disease. Nutr Res 12:1383-1392, 1992.
 
22) Ogborn MR, Nitschmann E, Bankovic-Calic N, et al:Dietary conjugated linoleic acid reduces PGE2 release and interstitial injury in rat polycystic kidney disease. Kidney Int 64:1214-1221, 2003.
PubMed
23) Sankaran D, Lu J, Bankovic-Calic N, et al:Modulation of renal injury in pcy mice by dietary fat containing n-3 fatty acids depends on the level and type of fat. Lipids 39 (3):207-214, 2004.
PubMed
24) Aukema HM, Yamaguchi T, Takahashi H, et al:Abnornal liped and fatty acid compositions of kidney from mice with polycystic kidney disease. LIPIDS 27 (6):429-435, 1992.
 
25) Yamaguchi T, Valli VEO, Philbrick D, et al:Effects of dietary supplementation with n-3 fatty acids on kidney morphology and the fatty acid composition of phospholipids and triglycerides from mice with polycystic kidney disease. Research Communications in Chemical Pathology and pharmacology 69 (3):335-351, 1990.
 
26) Ogborn MR, Nitschmann E, Bankovic-Calic N, et al:The effet of dietary flazseed supplementation on organic anion and osmolyte content and excreion in rat polycystic kidney disease. Biochem Cell Biol. /Biochim Bilo Cell 76 (2-3):553-559, 1998.
 
27) Igarashi P, SomLo S:Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 13:2384-2398, 2002.
PubMed
28) Chauveau D, Pirson Y, Le Moine A, et al:Extrarenal manifestations in autosomal dominant polycystic kidney disease. Adv Nephrol Necker Hosp 26:265-289, 1997.
PubMed
29) Lowden D, Lindermann G, Merlino G, et al:Renal cysts in transgenic mice expressing transforming growth factor-alpha. J Lab Clin Med 124:386-394, 1994.
 
30) Gattone VN, Kuensler K, Lindemann G, et al:Renal expression of a transforming grwoth factor-alpha transgene accelerates the progression of inherited, slowly progressive polycystic kidney disease in the mouse. J Lab Clin Med 127:214-222, 1996.
 
31) Sweeney Jr. WE, Chen Y, Nakanishi K, et al:Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int 57:33-40, 2000.
 
32) Richards WG, Sweeney WE, Yoder B, et al:Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J Clin Inves 101:935-939, 1998.
 
33) Sweeney Jr WE, hamahira K, Sweeney J, et al:Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. Kidney Int 64:1310-1319, 2003.
PubMed
34) Torres VE, Sweeney WE Jr, Wang X, et al:Epidermal growth factor receptor tyrosin kinase inhibition is not protective in PCK rats. Kiney Int 66:1766-1773, 2004.
 
35) Torres VE, Sweeney WE Jr, Wang X, et al:EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney Int 64:573-1579, 2003.
 
36) Noonberg S, Benz C:Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily. Drugs 59:753-767, 2000.
 
37) Dell KM, Nemo R, Sweeney WE Jr, et al:A novel inhibitor of tumor necrosis factor-a converting enzyme ameliorates polycystic kidney disease. Kidney Int 60:1240-1248, 2001.
PubMed
38) Tao Y, Kim J, Faubel S, et al:Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Pro Nat Acad Sience 102 6954-6959, 2005.
 
39) Tanner GA, Vijayalakshmi K, Tanner JA:Effects of potassium citrate/Citric acid intake in amouse model of polycystic kidney disease. Nephron 84:270-273, 2000.
 
40) Tanner GA, Tanner JA:Citrate therapy for polycystic kidney disease in rats. Kidney Int 58:1859-1869, 2000.
PubMed
41) Torres VE, Cowley BD Jr, Brander MG, et al:Long-term ammonium chloride or sodium bicarbonate treatment in two models of polycystic kidney disease. Exp Nephrol 9:171-180, 2001.
PubMed
42) Tomobe K, Philbrick D, Aukema H, et al:Early dietaty protein restriction slows disease progression and lengthens survival in mice with polycystic kidney disease. J Am Soc Nephrol 5:1355-1360, 1994.
 
43) Ogborn M, Sareen S:Amelioration of polycystic kidney disease by modification of dietary protein intake in the rat. J Am Soc Nephrol 6:1649-1654, 1995.
 
44) Tomobe K, Philbrick D, Ogborn M, et al:Effect of dietary soy protein and genistein on disease progression in mice with polycystic kidney disease. Am J kidney dis 1:55-61, 1998.
PubMed
45) Ogborn M, Bankovic-calic N, Shoesmith C, et al:Soy protein modification of rat polycystic kidney disease. Am J Pathol 274:F541-549, 1998.
 
46) Aukema H, Housini I, Rawling J:Dietary soy protein effects on disease and IGF-I in male and female Han:SPRD-cy rats. Kidney Int 59:52-61, 2001.
 
47) Schaffner D, Barrios R, Massey C, et al:Targeting of the rat T24 oncogene to the proximal convoluted tubules in transgenic mice results in hyperplasia and polycystic kidneys. Am J Pathol 142:1051-1060, 1993.
 
48) Oliff A:Farnesyltransferase inhibitors:Targeting the moleculer basis of cancer. Biochim Biophys Acta 1423:C19-C30, 1999.
 
49) Hill B, Perrin D, Kruczynski A:Inhibition of RAS-targeted prenylation:Protein farnesyl transferase inhibitors revisited, Crit Rev Oncol Hematol 33:7-23, 2000.
PubMed
50) Gile R, Cowley B Jr, Gattone VII, et al:Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney Dis 26:501-507, 1995.
 
51) Aukema H, Housini I, Rawling J:Dietary soy protein effects on disease and IGF-I in male and female Han:SPRD-cy rats. Kidney Int 59:52-61, 2001.
 
52) Muto S, Aiba A, Saito Y, et al:Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 11:1731-1742, 2002.
PubMed
53) Hill B, Perrin D, Kruczynski A:Inhibition of RAS-targeted prenylation:Protein farnesyl transferase inhibitors revisited. Crit Rev Oncol Hematol 33:7-23, 2000.
PubMed
54) Chauveau D, Pirson Y, Le Moine A, et al:Extrarenal manifestations in autosomal dominant polycystic kidney disease. Adv Nephrol Necker Hosp 26:265-289, 1997.
PubMed
55) Yamaguchi T, Pelling J, Ramaswamy N, et al:cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 57:1460-1471, 2000.
PubMed
56) Nakamura T, Ushiyama C, Suzuki S, et al:Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen and plasma levels of metalloproteinase-9 in polycystic kidney disease. Am J Nephrol 20:32-36, 2000.
PubMed
57) Obermuller N, Morente N, Kranzlin B, et al:A possible role for metalloproteinases in renal cyst development. Am J Physiol Renal Physiol 280:F540-550, 2001.
PubMed
58) Ricker JL, Mata JE, Iversen PL, et al:C-myc antisense oligonucleotide treatment ameliorates murine ARPKD. Kidney Int 61:S125-131, 2002.
PubMed
59) Grantham. JJ:Time to treat polycystic kidney disease like the neoplastic disorders that they are. Kidney Int 57:339-340, 2000.
PubMed
60) Woo D, Tabancay A Jr, Wang C:Microtubule active taxanes inhibit polycystic kidney disease progression in cpk mice. Kidney Int 51:1613-1618, 1997.
PubMed
61) Martinez J, Cowley B, Gattone VII, et al:The effect of paclitaxel on the progression of polycystic kidney disease in rodents. Am J Kidney Dis 29:435-444, 1997.
 
62) Edmunds JW, Jayapalan S, DiMarco NM, et al:Creatine supplementation increases renal disease progression in Han:SPRD-cy rats. Am J Kidney Dis 37:73-78, 2001.
 
63) Belibi FA, Wallace DP, Yamaguchi T, et al:The effect of caffeine on renal epithelial cells from patients with autosomal dominant poycystic kidney disease. J Am Soc Nephrol 13:2723-2729, 2002.
PubMed
64) Tanner GA, Tanner JA:Chronic caffeine consumption exacerbates hypertension in rats with polycystic kidney disease:Chronic caffeine consumption exacerbates hypertension in rats with polycystic kidney disease. Am J Kidney Dis 38:1089-1095, 2001.
PubMed
65) Orth SR:Smoking-a renal risk factor. Nephron 86:12-26, 2000.
PubMed
66) Munemura C, Uemaso J, Kawasaki H:Epidermal growth factor and endothelin in cyst fluid from autosomal dominant polycystic disease case. Am J Kidne Dis 24:561-568, 1994.
 
67) Hocher B, Zart R, Schwarz A, et al:Renal endothelin system in polycystic kidny disease. J Am So Nephrol 9:1169-1177, 1998.
 
68) Hocher B, Kalk P, Slowinski T, et al:ETA recptor blockade induces tubular cell proliferation and cyst growth in rats with polycystic kidney disease. J Am Soc Nephrol 14:367-376, 2003.
 
69) Keith DS, Torres VE, Johnson Cm, et al:Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in han:SPRD rat. Am J Kidney Dis 24:491-498, 1994.
 
70) Ogborn MR, Sareen S, Pinette G:Cilazapril delays progression of hypertension and uremia in rat polycystic kidney disease. Am J Kidney Dis 26:942-946, 1995.
PubMed
71) Torre VE, Bengal RJ, Litwiller RD, et al:Aggravation of polycystic kidney disease in han:SPRD rats by buthionine sulfoximine. J Am Soc Nephrol 8:1283-1291, 1997.
 
72) Yoshida I, Bengal R, Torres VE:Gender-dependent effect on L-NAME on polycystic kidney disease in han:SPRD rats. Am J Kidney Dis 35:930-936, 2000.
 
73) Cowly BD Jr, Grantheam JJ, Muessel BS, et al:Modification of disease progression in rats with inherited polycystic kidney disease. Am J Kidney Dis (6):865-879, 1996.
 
P.223 掲載の参考文献
1) Ruggenenti P, Remuzzi A, Ondei P, et al:Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 68:206-216, 2005.
PubMed
2) Silva P, Stoff JS, Leone DR, et al:Mode of action of somatostatin toinhibit secretion by shark rectal gland. Am J Physiol 249:R329-R334, 1985.
PubMed
3) Silva P, Schenermann M, Gard-Weiss T, et al:Somatostatin inhibits CNP-induced stimulation of shark rectal gland. Bull Mt Desert Island Biol Lab 40:25-29, 1991.
 
4) Reubi JC, Horisberger U, Studer UE, et al:Human kidney as target for somatostatin:High affinity receptors in tubules and vasa recta. J CIin Endocrinol Metab 77:1323-1328, 1993.
 
5) Lamberts SW, Van Der Lely AJ, De Herder WW, et al:Octreotide. N Engl J Med 334:246-254, 1996.
PubMed
6) Reichlin S:Somatostatin. N Engl J Med 309:1495-1501 and 1556-1563, 1983.
 
7) Trendle MC, Moertel CG, Kvols LK:Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer 79:830-834, 1997.
PubMed
8) van Dijk MA, Kamper AM, van Veen S, et al:Effect of simvastatin in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 16:2152-2157, 2001.
PubMed
9) Klahr S, Levey AS, Beck GJ, et al:The effects of dietary protein restriction and bllodpressure control on the progression of chronic renal disease. N Eng J Med 330 (13):877-884, 1994.
 
10) Modification of diet in renal disease study group (prepared by Klahr S, Breyer JA, Beck GJ, et al):Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. J Am Soc Nephrol 5:2037-2047, 1995.
 
P.232 掲載の参考文献
1) 日本透析医学会統計調査委員会:わが国の慢性透析療法の現況(2004年12月31日現在) . 透析会誌 39:1-22, 2006.
 
2) Ishikawa I:Autosomal dominant polycystic kidney. Nippon Rinsho-Japanese Journal of Clinical Medicine 60 Suppl 1:541-52, 2002.
 
2) Fourtounas C, Panteris V, Valis D:Survival after end-stage renal disease in autosomal dominant polycystic kidney disease. American Journal of Kidney Diseases 39 (3):660, 2002.
PubMed
4) Higashihara E, Nutahara K, Kojima M, et al:Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease. Japan Nephron 80 (4):421-7, 1998.
PubMed
5) Zeier M, Jones E, Ritz E:Autosomal dominant polycystic kidney disease-the patient on renal replacement therapy. Nephrology Dialysis Transplantation 11 Suppl 6:18-20, 1996.
 
6) Ubara Y, Tagami T, Hishino J, et al:ADPKD patients on dialysis. Nippon Rinsho-Japanese Journal of Clinical Medicine 62 Suppl 6:20-30, 2004.
 
7) Ritz E, Jones E, Waldherr R, et al:The patient with ADPKD on maintenance hemodialysis. Contributions to Nephrology 115:33-8, 1995.
PubMed
8) Hadimeri H, Johansson AC, Haraldsson B, et al:CAPD in patients with autosomal dominant polycystic kidney disease. Peritoneal Dialysis International 18 (4):429-32, 1998.
PubMed
9) Ishikawa I, Saito Y:Volume changes in autosomal dominant polycystic kidneys after the initiation of hemodialysis. Nephron 65 (4):649-50, 1993.
PubMed
10) Norby SM, Torres VE:Complications of autosomal dominant polycystic kidney disease in hemodialysispatients. Seminars in Dialysis 13 (1):30-5, 2000.
 
11) Christophe JL, van Ypersele de Strihou C, Pirson Y:Complications of autosomal dominant polycystic kidney disease in 50 haemodialysed patients. A case-control study. The UCL Collaborative Group. Nephrology Dialysis Transplantation 11 (7):1271-6, 1996.
 
12) Ubara Y, Katori H, Tagami T, et al:Transcatheter renal arterial embolization therapy on a patient with polycystic kidney disease on hemodialysis. American Journal of Kidney Diseases 34 (5):926-31, 1999.
PubMed
13) Ishikawa I, Chikamoto E, Nakamura M, et al:High incidence of common bile duct dilatation in autosomal dominant polycystic kidney disease patients. American Journal of Kidney Diseases 27 (3):321-6, 1996.
PubMed
P.236 掲載の参考文献
1) Pafrey PS, Bear JC, Morgan J, et al:The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N Engl J Med 323:1085-1090, 1990.
 
2) The European Polycystic Kidney Disease Consortium:Polycystic kidney disease 1 gene encodes a 14kb transcript and lies within a duplicated region on chromosome 16. Cell 77:881-894, 1994.
 
3) Mochizuki T, Wu G, Hayashi T, et al:PKD2. a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272:1339-1342, 1996.
PubMed
4) Hanning VL, Hopkins JR, Johnson HK, et al:Presymptomatic testing for adult onset polycystic kidney disease in at-risk kidney transplant donors. Am J Med Genet 40:425-428, 1991.
 
5) 新村浩明, 田邉一成, 東間紘:のう胞性腎疾患の腎移植. 腎と透析51:475-479, 2001.
 
6) Fick GM, Gabow PA:The urgent complications of autosomal dominant polycystic kidney disease. J Crit Illn 7:1905-1920, 1992.
 
7) Kaehny WD, Everson GT:Extrarenal manifestations of autosomal dominant polycystic kidney disease. Semin Nephrol 11:661-670, 1991.
PubMed
8) Sceff RT, Zuckerman G, Harter H, et al:Diverticular disease in patients with chronic renal failure due to polycystic renal disease. Ann Intern Med 92:202-204, 1980.
 
9) Andreoni KA, Pelletier RP, Elkhammas EA, et al:Increased incidence of gastrointestinal surgical complications in renal transplant recipients with polycystic kidney disease. Transplantation 67:262-266, 1999.
PubMed
10) Florijin KW, Chang PC, Woude FJ, et al:Long-term cardiovascular morbidity and mortality in autosomal dominant polycystic kidney disease patients after renal transplantation. Transplantation 57:73-81, 1994.
 
11) Hadimieri H, Norden G, Friman S, et al:Autosomal dominant polycystic kidney disease in a kidney transplant population. Nephrol Dial Transplant 12:1431-1436, 1997.
 
12) Shiroyanagi Y, Tanabe K, Hashimoto Y, et al:Kidney transplantation in the recipient with autosomal dominant polycystic kidney disease. Transplant Proc 32:1841-1843, 2000.
PubMed

IV 周辺の嚢胞性腎疾患

P.239 掲載の参考文献
1) Hoefele J, Otto E, Felten H, et al:Clinical histological presentation of 3 siblings with mutations in the NPHP4 gene. Am J Kidney Dis 43 (2):358-364, 2004.
PubMed
2) Otto EA, Schermer B, Obara T, et al:Mutations INVS encoding inversin cause nephronophthisis type 2, linking renal cystic disease to the function of primary cilia and left right axis determination. Nat Genet 34 (4):413-420, 2003.
 
3) Donaldson J, Dise R, Ritchie M, et al:Nephrocystin-conserved domains involved in targeting to epithelial cell-cell junctions, interaction with filamins, and establishing cell polarity. J Biol Chem 277(32):29028-29035, 2002.
PubMed
4) Nurnberger J, Kribben A, Opazo Saez A, et al:The invs gene encodes a microtuble associated protein. J Am Soc Nephrol 15 (7):1700-1710, 2004.
 
5) Eley L, Turnpenny L, Yates LM, et al:Aperspective on inversin. Cell Biol Int 28 (2):119-124, 2004.
 
6) Hildebrandt F, Otto E, Rensing C, et al:Anovel gene encoding an SH3 domain protein is mutated in nephronophthisis type 1. Nat Genet 17 (2):149-153, 1997.
 
P.240 掲載の参考文献
1) Wolf MT, Mucha BE, Attanasio M, et al:Telomeric refinement of the MCKD1 locuson chromosome 1q21. Kidney Int 66 (5):580-585, 2004.
 
2) Dahan K, Devuyst O, Smaers M, et al:A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J Am Soc Nephrol 14 (11):2883-93, 2003.
PubMed
3) Wolf MT, Mucha BE, Attanasio M, et al:Mutations of the uromodulin gene in MCKD type 2 patients cluster in exon 4, which encodes three EGF-like domains. Kidney Int 64 (5):1580-1587, 2003.
PubMed
4) Rampoldi L, Caridi G, Santon D, et al:Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin expory dynamics. Hum Mol Genet 12 (24):3369-3384, 2003.
PubMed
P.241 掲載の参考文献
1) Thauvin-Robinet C, Cossee M, Cormier-Daire V, et al:Clinical, molecular, and genotype-phenotype correlation studies from 25 cases of oral-facial-digital syndrome type 1:a French and Belgian collaborative study. J Med Genet 43 (1):54-61, 2006.
PubMed
2) Romio L, Fry AM, Winyard PJ, et al:OFD1 is a centrosomal/Basal body protein expressed during mesenchymal-epithelial transtion in human nephrogenesis. J Am Soc Nephrol 15 (10):2556-2568, 2004.
 
3) Romio L, Wright V, Price K, et al:OFD1, the gene mutated in oral-facial-digital syndrome type1, is expressed in the metanephros and in human embryonic renal mesenchymal cells. J Am Soc Nephrol 14 (3):680-689, 2003.
 
4) 大庭健一, 園田徹, 政所治道, ほか:四世代5人に認められたOral-facial-digita1症候群. 小児科臨床 41(6):1253-6, 1988.
 
5) de Conciliis L, Marchitiello A, Wapenaar MC, et al:Characterization of cxorf5 (71-7A), a novel human cDNA mapping to Xp22 and encoding a protein containing coiled-coil α-helical domains. Genomics 51 (2):243-250, 1998.
 
P.244 掲載の参考文献
1) Scolari F, Viola BF, Prati E, et al:Medullary cystic kidney disease:past and present. Contrib Nephrol 136:68-78, 2001.
PubMed
2) Hart TC, Gorry MC, Hart PS, et al:Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricemic nephropathy. J Med Genet 39:882-892, 2002.
 
3) Hildebrandt F, Omram H:New insights:nephronophthisis-medullary cystic kidney disease. Pediatr Nephrol 16:168-76, 2001.
PubMed
4) Hildebrandt F, Otto E:Molecular genetics of nephronophthisis and medullary cystic kidney disease. J Am Soc Nephrol 11:1753-61, 2000.
 
5) Scolari F, Puzzer D, Amoroso A, et al:Identification of a new locus for medullary cystic disease, on chromosome 16p12. Am J Hum Genet 64:1655-60, 1999.
PubMed
6) Pennica D, Kohr WJ, Kuang WJ, et al:Identification of human uromodulin as the Tamm. Horsfall urinary glycoprotein. Science 236:83-88, 1987.
PubMed
7) Rampoldi L, Caridi G, Santon D, et al:Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamics. Hum Mol Genet 12:3369-3384, 2003.
PubMed
P.246 掲載の参考文献
1) Dell KM, McDonald RA, Watkins SL, Avner ED:Polycystic kidney disease In Pediatric Nephrology. 5th ed, Avner ED, Harmon WE, Niaudet P (eds). p675-699, Lippincott Williams & Wilkins, Philadelphia, 2004.
 
2) Rampoldi L, Caridi G, Santon D, et al:Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamics. Hum Mol Genet 12:3369-3384, 2003.
PubMed
3) Kaplan BS, Gordon I, Pincott J, et al:Familial hypoplastic glomerulocystic kidney disease:adefinite entity with dominant inheritance. Am J Med Genet 34:569-573, 1989.
 
4) Bingham C, Bulman MP, Ellard S, et al:Mutations in the hepatocyte nuclear factor-1-beta gene are associated with familial hypoplastic glomerulocystic kidney disease. Am J Hum Genet 68:219-224, 2001.
PubMed
5) Horikawa Y, Iwasaki N, Hara M, et al:Mutation in hepatocyte nuclear factor-1-beta gene (TCF2) associated with MODY. (Letter) Nature Genet 17:384-385, 1997.
PubMed
6) Hiesberger T, Bai Y, Shao X, et al:Mutation of hepatocyte nuclear factor-1-beta inhibits Pkhd1 gene expression and produces renal cysts in mice. J Clin Invest 113:814-825, 2004.
PubMed
P.249 掲載の参考文献
1) Plon SE, Owens J: Tuberous sclerosis. UP To Date 14. 1.
 
2) Roach ES, Gomez MR, Northrup H:Tuberous sclerosis complex consensus conference:rivized clinical diagnostic criteria. J Child Neurol 13:624, 1998.
PubMed
P.254 掲載の参考文献
1) Latif F, Tory K, Gnarra J, et al:Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-20, 1993.
PubMed
2) Yao M, Kondo K, Shuin T, et al:Mutation of the von Hippel-Lindau disease gene in sporadic human renal cell carcinoma. Gann Monograph on Cancer Research 205-214, 1999.
 
3) Germline mutations in the von Hippel-Lindau disease (VHL) gene in Japanese VHL. Clinical Research Group for VHL in Japan. Hum Mol Genet 4 (12):2233-7, 1995.
 
4) Kaelin WG Jr:Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2 (9):673-82, 2002.
PubMed
P.256 掲載の参考文献
1) Burdet G:Thesis 479, 1920.
 
2) Mykytyn K, Nishimura DY, Serby CC, et al:Nat Genet 31:435-438, 2002.
 
3) Mykytyn K, Nishimura DY, Serby CC, et al:Am J Hum Genet 72 (2):429-37, 2003.
 
4) Kim JC, Badano JL, Sibold S, et al:Nat Genet 36 (5):462-70, 2004.
PubMed
5) Badano JL, Ansley SJ, Leitch CC, et al:Am J Hum Genet 72 (3):650-8, 2003.
PubMed
6) Ansley SJ, Badano JL, Blacque OE, et al:Nature 425 (6958):628-33, 2003.
PubMed
P.260 掲載の参考文献
1) Stuck KJ, Koff SA, Silver TM:Ultrasonographic features of multicystic dysplastic kidney:expanded diagnotic criteri. Radiology 143:217-221, 1982.
 
2) 小島美保, 東原英二:Multicystic dysplastic kidneyの合併症と治療. 小児内科 27 (3):29-32, 1995.
 
P.263 掲載の参考文献
1) Powell T, Shackman R, Johnson HD:Multilocular cysts of the kidney. Brit J Urol 23:142-152, 1951.
PubMed
2) Novic AC, Campbell ST:Renal tumor. In:Campbell's Urology, 8th ed, Walsh PC, Retik AB, Vaughan Jr ED, et al (eds), Vol 4, p2672-2731, Saunders, Philadelphia, 2002.
 
3) Nasssir A, Lollimore J, Gupta R, et al:Multilocular renal cell carcinoma:aseries of 12 cases and review of the literature. Urology 60:421-427, 2002.
 
4) Okada T, Yoshida H, Matsunaga T, et al:Nephron-sparing surgery for multilocular cyst of the kidney in a child. J Ped Surg 38:1689-1692, 2003.
 
5) Slywotzky CM, Bosniak MA:Localized cystic disease of the kidney. AJR 176:843-849, 2001.
PubMed
P.275 掲載の参考文献
1) Baert LUG:Microdissection findings of medullary sponge kidney. Urology 11 (6):637-640, 1978.
 
2) Higashihara E, Nutahara K, Tago K, et al:Unilateral and segmental medullary sponge kidney:Renal function and calcium excretion. J Urol 132:743-745, 1984.
PubMed
3) Modarelli RO, Wettlaufer JN:Surgically documented segmental medullary sponge kidney:case report. J Urol 117:244-245, 1977.
PubMed
4) Beitzke H:Uber Zysten in Nieremark. Charite-Ann 32:285, 1908.
 
5) Lenarduzzi G:Repert pielografico poco commune (dilatazione delle vie urinarie intrarenali). Radiol Med 26:346, 1939.
 
6) Cacchi R, Ricci V:Sur une rare maladie kystique multiple des pyramides renales le "rein en eponge". J Urol Nephrol (Paris) 55:497, 1949.
 
7) Kuiper JJ:Medullary sponge kidney, in Cystic diseases of the kidney. Gardner KD (ed). A Wiley Biomedical Publication, 1976.
 
8) Hamburger J, et al:Nephrology. WB Saunders, Philadelphia, 1968.
 
9) Yendt ER:Medullary sponge kidney. In:Diseases of the kidney. 5th ed. Schrier RW, Gottschalk CW (eds). p525-533, Little, Brown and Company, Boston, 1993.
 
10) Fick GM, Gabow PA:Hereditary and acquired cystic disease of the kidney. Kidney Int 46:951-964, 1994.
PubMed
11) Khoury Z, Brezis M, Mogle P:Familial medullary sponge kidney in association with congenital absence of teeth (Anodontia). Nephron 48:231-233, 1988.
PubMed
12) Kuiper JJ:Medullary sponge kidney in three generations. New York State J Medicine 15:2665-2669, 1971.
 
13) Copping GA:Medullary sponge kidney:Its Occurrence in a father and daughter. Canad Med Ass J 96:608-611, 1967.
 
14) Palubinskas AJ:Medullary sponge kidney. Radiology 76:911, 1961.
PubMed
15) Mayall GF:The incidence of medullary sponge kidney. Radiol 21:171-174, 1970. 1
 
16) Bernstein J, Gardner KD Jr:Cystic disease of the kidney and renal dysplasia. In:Campbell's Urology. 5th ed, Walsh PC, Gittes RF, Perlmutter AD, et al (eds). p1760, WB Saunders, Philadelphia, 1986.
 
17) Lavan JN, Neals FC, Posen S:Urinary calculi:Clinical, biochemical and radiogical studies in 619 patients. Med J Aust 2:1049, 1971.
 
18) Parks JH, Coe FL, Strauss AL:Calcium nephrolithiasis and medullary sponge kidney in woman. N Engl J Med 306 (18):1088-1091, 1982.
PubMed
19) Sage MR, Lawson AD, Marshall VR, et al:Medullary sponge kidney and urolithiasis. Clin Radiol 33:435-438, 1982.
PubMed
20) Wikstrom B, Backman U, Danielson BG:Ambulatory diagnostic evaluation of 38 recurrent renal stone formers:Aproposal for clinical classification and investigation. Klin Wochenschr 61:85, 1983.
 
21) Yendt ER:Medullary sponge kidney. In:The Cystic Kidney. Gardner KD Jr, Bernstein J (eds). p379, Kluwer Academic Publishers, The Netherlands, 1990.
 
22) 宮内大成, 伊藤晴夫, 村上光右, ほか:海綿腎の臨床的研究. 日本泌尿器科学会誌76 (4):540-545, 1985.
 
23) 木下博之:海綿腎の臨床的検討. 日本泌尿器科学会誌81 (3):372-379, 1990.
 
24) Sprayregen S, Strasberg Z, Naidich TS:Medullary sponge kidney and congenital total hemihypertrophy. New York State J Med 2768-2772, December 1, 1973.
 
25) Harris RE, Fuchs EF, Kaempe MJ:Medullary sponge kidney and congenital hemihypertrophy:Case report and literature review. J Urol 126:676-678, 1981.
 
26) Afonso DN, Oliveira AG:Medullary sponge kidney and congenital hemi-hypertrophy. Br J Urol 62:187-188, 1988.
PubMed
27) Tomooka Y, Onitsuka H, Goya T, et al:Congenital hemihypertrophy with adrenal adenoma and medullary sponge kidny. Br J Urol 61 (729):851-853, 1988.
 
28) Indridason OS, Thomas L, Berkoben M:Medullary sponge kidney associated with congenital hemihypertrophy. J Am Soc Nephrol 7 (8):1123-1130, 1996.
PubMed
29) Rommel D, Pirson Y:Medullary sponge kidney-part of a congenital syndrome. Nephrol Dial Transplant 16:634-636, 2001.
PubMed
30) Stoll C, Alembik Y, Steib JP, et al:Twelve cases with hemihypertrophy:Etiology and follow up. Genet Couns 4:119-126, 1993.
PubMed
31) Levine AS, Michael AF Jr:Ehlers-Danlos syndrome with renal tubular acidosis and medullary sponge kidneys. J Pediatrics 71 (1):107-113, 1967.
 
32) Schoeneman MJ, Plewinska M, Mucha M, et al:Marfan syndrome and medullary sponge kidney:case report and speculation on pathogenesis. Int J Pediatric Nephrology 5 (2):103-104, 1984.
 
33) Abreo K, Steele TH:Simultaneous medullary sponge and adult polycystic kidney disease. Arch Intern Med 142:163-165, 1982.
PubMed
34) Lambrianides AL, John DR:Medullary sponge disease in horseshoe kidney. Urology 29:426-427, 1987.
PubMed
35) Diouf B, Ka EHF, Calender A, et al:Association of medullary sponge kidney disease and multiple endocrine neoplasia type IIA due to RET gene mutation:is there a causal relationship? Nephrol Dial Transplant 15:2062-2066, 2000.
 
36) Higashihara E, Nutahara K, Tago K, et al:Medullary sponge kidney and renal acdification defect. Kidney Int 25:453-459, 1984.
 
37) Deck MDF:Medullary sponge kidney with renal tubular acidosis. A report of 3 cases. J Urol 94:330-335, 1965.
 
38) Levin NW, Rosenberg B, Swi S, et al:Medullary cystic disease of the kidney, with some observations on ammonium excretion. Am J Medicine 30:807-812, 1961.
 
39) Granberg P-0, Lagergren C, Theve NO:Renal function studies in medullary sponge kidney. Scand J Urol Nephrol 5:177-180, 1971.
 
40) Kumagai I, Matsuo S, Kato T:Acase of incomplete renal tubular acidosis (type 1) associated with medullary sponge kidney followed by nephrocalcinosis. J Urol 123:250-252, 1980.
 
41) 東原英二:腎乳頭集合管の生理-基礎と臨床-. 日本腎臓学会誌28 (7):837-848, 1986.
 
42) 東原英二, 奴田原紀久雄, 武内巧:特集:尿細管性アシドーシス. 泌尿器科的腎疾患と酸排泄障害-髄質海綿腎を中心として-. 日本臨床43 (9):163-168, 1985.
 
43) Burke JR, Inglis JA, Craswell PW, et al:Juvenile nephronophthisis and medullary cystic disease the same disease (report of a large family with medullary cystic disease associated with gout and epilepsy). Clin Nephrol 18 (1):1-8, 1982.
PubMed
44) Ram MD, Chisholm GD:Cystic disease of renal pyramids (Medullary sponge kidney). Br J Urol 41:280-287.
PubMed
45) Strauss MB:Clinical and pathological aspects of cystic disease of the renal medulla. Annals Int Medicine 57 (3):373-381, 1962.
 
46) Kiser RL, Wolf MTF, Martin JL, et al:Medullary cystic kidney disease type l in a large native American kindred. Am J Kidney Dis 44 (4):611-617, 2004.
 
47) Scolari FS, Caridi G, Rampoldi L, et al:Uromodulin storage disease:Clinical aspects and mechanisms. Am J Kidney Dis 44 (6):987-999, 2004.
 
48) Kuiper JJ:Medullary sponge kidney. Perspect Nephrol Hypertens 4:151, 1976a.
 
49) Higashihara E, Nutahara K, Niijima T:Renal hypercalciuria and metabolic acidosis associated with medullary sponge kidney:Effect of alkali therapy. Urol Res 16:95-100, 1988.
PubMed
50) Ekstrom T, Engfeldt B, Langergren C, et al:Medullary Sponge Kidney. Almquist and Wiksells, Stockholm, 1959.
 
51) Harrison AR, Rose GA:Medullary sponge kidney. Urol Res 7:197, 1979.
PubMed
52) Maschio G, Tessitore N, D:Angelo A, et al:Medullary sponge kidney and hyperparathyroidism:A puzzling association. Am J Nephrol 2:77-84, 1982.
PubMed
53) Higashihara E, Carter NW, Pucacco L, et al:Aldosterone effects on papillary collecting duct pH profile of the rat. Am J Physiol 246:F725-F731, 1984.
PubMed
54) O:Neill M, Breslau NA, Pak CYC:Metabolic evaluation of nephrolithiasis in patients with medullary sponge kidney. JAMA 245 (12):1233-1237, 1981.
 
55) Poy RKP, Niall JF:Tubular function in medullary cystic disease of the kidney. Aust Ann Med 13:334-338, 1964.
 
56) Backman U, Danielson BG, Fellstrom B, et al:Clinical and laboratory findings in patients with medullary sponge kidney. In:Urolithiasis, Clinical and Basic Research. Smith LH, Robertson WG, Finlayson B (eds). p113-120, Plenum Press, New York, 1981.
 
57) Osther PJ, Hansen AB, Roehl HF:Renal acidification defects in medullary sponge kidney. Br J Urol 61:392-394, 1988.
 
58) Osther PJ, Mathiasen H, Hansen AB, et al:Urinary acidification and urinary excretion of calcium and citrate in woman with bilateral medullary sponge kidney. Urol Int 52:126-130, 1994.
PubMed
59) Meyers AM, Whalley N, Martins M, et al:Recurrent renal calculi in patients with medullary sponge kidney. In:Urolithiasis 2, Ryall R, Bais R, Marshall VR, et al (eds). p375-378, Plenum Press, New York, 1994.
 
60) Green J, Szylman P, Sznajder II, et al:Renal tubular handling of potassium in patients with medullary sponge kidney. Arch Intern Med 144:2201-2204, 1984.
PubMed
61) Dlabal CPW, Jordan MRM, Dorfman MSG:Medullary sponge kidney and renal-leak hypercalciuria. JAMA 241 (14):1490-1491, 1979.
 
62) Gremillion MDH, Kee MJW, Mclntosh CDA:Hyperparathyroidism and medullary sponge kidney. JAMA 237 (8):799-800, 1977.
 
63) Higashihara E, Kitamura T, Munakata A, et al:Medullary sponge kidney and hyperparathyroidism Urology 31 (2):155-158, 1988.
PubMed
64) Rao DS, Frame B, Block MA, et al:Acause of hypercalciuria and renal stones in patients with medullary sponge kidney. JAMA 237 (13):1353-1355, 1977.
 
65) Mcllwaine CLK, Jalan KN:Hyperparathyroidism associated with medullary sponge kidney. BrJUrol 40:202-205, 1968.
 
66) Stella FJ, Massry SG, Kleeman CR:Medullary sponge kidney associated with parathyroid associated with parathyroid adenoma. Nephron 10:332-336, 1973.
PubMed
67) Hellman DE, Kartchner M, Komar N, et al:Hyperaldosteronism, hyperparathyroidism, medullary sponge kidneys, and hypertension. JAMA 244 (12):1351-1353, 1980.
PubMed
68) Deliveliotis Ch, Sofras F, Karagiotis E, et al:Management of lithiasis in medullary sponge kidneys. Urol Int 57:185-187, 1996.
 
69) Harrison AR, Rose GA:Medullary sponge kidney. Urol Res 7:197-207, 1979.
PubMed
70) Higashihara E, Aso Y:Renal tubule defects in medullary sponge kidney disease. Nephrology Proceedings of the Xth International Congress of Nephrology, Editor AM Davison. p1138-1152, Bailliere Tindal, London, 1988.
 
P.281 掲載の参考文献
1) Kissane JM, Smith MG:Pathology of Infancy and Childhood. 2nd ed. p587, CV Mosby, St Louis, 1975.
 
2) Al-Said J, Brumback MA, Moghazi S, et al:Reduced renal function in patients with simple renal cysts. Kidney Int 65:2303-2308, 2004.
PubMed
3) Pedersen JF, Emamian SA, Nielsen MB:Significant association between simple renal cysts and arterial blood pressure. Br J Urol 79:688-691, 1997.
PubMed
4) Rane A:Laparoscopic management of symptomatic simple renal cysts. Int Urol Nephrol 36:5-9, 2004.
PubMed
5) Glassberg KI:Renal dysgenesis and cystic disease of the kidney. In:Campbell's Urology 8th ed. Walsh PC, Retik AB, Vaughan ED Jr, et al (eds). p1925-1994, Saunders, Philadelphia, 2002.
 
P.282 掲載の参考文献
1) Glassberg KI:Renal dysgenesis and cystic disease of the kidney. In:Campbell's Urology 8th ed. Walsh PC, Retik AB, Vaughan ED Jr, et al (eds) . p1925-1994, Saunders, Philadelphia, 2002.
 
P.286 掲載の参考文献
1) Dunnill MS, Millard PR, Oliver D:Acquired cystic disease of the kidneys:a hazard of long-term intermittent maintenance haemodialysis. J Clin Pathol 30:868-877, 1977.
PubMed
2) 石川勲:多嚢胞化萎縮腎. 腎と透析17:341-348, 1984.
 
3) Ishikawa I:Uremic acquired renal cystic disease. Natural history and complications. Nephron 58:257-267, 1991.
PubMed
4) Ishikawa I, Saito Y, Onouchi Z, et al:Development of acquired cystic disease and adenocarcinoma of the kidney in glomerulonephritic chronic hemodialysis patients. Clin Nephrol 14:1-6, 1980.
PubMed
5) Ishikawa I, Onouchi Z, Saito Y, et al:Sex differences in acquired cystic disease of the kidney on long-term dialysis. Nephron 39:336-340, 1985.
PubMed
6) Ishikawa I, Saito Y, Asaka M, et al:Twenty-year follow-up of acquired renal cystic disease. Clin Nephrol 10:153-159, 2003.
 
7) Ishikawa I, Shikura N, Nagahara M, et al:Comparison of severity of acquired renal cysts between CAPD and hemodialysis. Adv Perit Dial 7:91-95, 1991.
PubMed
8) Ishikawa I, Yuri T, Kitada H, et al:Regression of acquired cystic disease of the kidney after successful renal transplantation. Am J Nephrol 3:310-314, 1983.
PubMed
9) Ishikawa I:Acquired cystic disease:mechanisms and manifestations. Semin Nephrol 11:671-684, 1991.
PubMed
10) 石川勲:透析患者にみられる腎癌の現況:2004年度アンケート調査報告と1982年度からのまとめ. 透析会誌38:1689-1700, 2005.
 
11) Ishikawa I:Comparison of cyst characteristics in acquired and inherited renal cystic disease. Advances in the Pathogenesis of Polycystic Kidney Disease, Carone FA, Dobbie JW (eds). p85-90, Baxter Healthcare Corporation, Chicago, Illinois, 1990.
 
12) Ishikawa I:Cancer in dialysis patients. Cancer and the Kidney, Cohen EP (eds). p227-247, Oxford University Press, Oxford, 2005.
 
P.289 掲載の参考文献
1) Glassberg KI:Renal dysgenesis and cystic disease of the kidney. In:Campbell's Urology 8th ed. Walsh PC, Retik AB, Vaughan ED Jr, et al (eds). p1925-1994, Saunders, Philadelphia, 2002.
 
2) Bagley DH:Endoscopy:Upper Tract. In:Comprehensive Urology. Weiss RM, George N JR, O:Reilly PH (eds). p161-173, Mosby, London, 2001.
 
P.291 掲載の参考文献
1) Bergman H, Nehme DA:Unilateral polycystic renal disease. NY State J Med 64:2465-2469, 1964.
 
2) Lee JKT, McClennan BL, Kissane JM:Unilateral polycystic kidney disease. Am J Roentgenol 130:1165-1167, 1978.
 
3) Levine E, Huntrakoon M:Unilateral renal cystic disease:CT findings. J Compt Assist Tomogr 13:273-276, 1989.
 
4) Hwang DY, Ahn C, Lee JG, et al:Unilateral renal cystic disease in adults. Nephrol Dial Transplant 14:1999-2003, 1999.
PubMed
5) Lin SP, Chang JM, Chen HC, et al:Unilateral renal cystic disease-report of one case and review of literature. Clin Nephrol 57:320-324, 2001.
 

付録

P.309 掲載の参考文献
1) The European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1 gene encodes a 14kb transcript and lies within a duplicated region on chromosome 16. Cell 77:881-894, 1994.
 
2) Mochizuki T, Wu G, Hayashi T, et al:PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272:1339-1342, 1996.
PubMed
3) Gonzalez-Perrett S, Batelli M, Kim K, et al:Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca2+-permeable nonselective cation channel. Proc Natl Acad Sci USA 98:1182-1187, 2001.
PubMed
4) Koulen P, Cai Y, Geng L, et al:Polycystin-2 is an intracellular calcium release channel Nat Cell Biol 4:191-197, 2002.
PubMed
5) Hanaoka K, Qian F, Boletta A, et al:Co-assembly of polycystin-1 and-2 produces unique cation-permeable currents. Nature 408:990-994, 2000.
PubMed
6) Yoder BK, Hou X, Guay-Woodford LM:The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol 13:2508-2516, 2002.
 
7) Nauli SM, Alenghat FJ, Luo Y, et al:Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 33:129-137, 2003.
PubMed
8) Hanaoka K, Guggino WB:cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 11:1179-1187, 2000.
 
9) Yamaguchi T, Wallace DP, Magenheimer BS, et al:Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 279:40419-40430, 2004.
 
10) Parfrey PS, Bear JC, Morgan J, et al:The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N Engl J Med 323:1085-1090, 1990.
PubMed
11) Persu A, Stoenoiu MS, Messiaen T, et al:Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 11:229-241, 2002.
PubMed
12) Peters DJM, Sandkuijil LA:Genetic heterogeneity of polycystic kidney disease in Europe. Contrib Nephrol 97:128-139, 1992.
 
13) Higashihara E, Horie S:Genetic study of ADPKD in Japan. Kidney Int 47:729, 1995.
 
14) Chan KW:Adult polycystic kidney disease in Hong Kong Chinese. An autopsy study Pathology 25:229-232, 1993.
 
15) Davies F, Coles GA, Happer PS, et al:Polycystic kidney disease Re-evaluated:A population-based study. Q J Med 79:477-485, 1991.
 
16) Higashihara E, Nutahara K, Kojima M, et al:Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. Nephron 80:421-427, 1998.
PubMed
17) Johnson AM, Gabow PA:Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol 8:1560-1567, 1997.
PubMed
18) Choukroun G, Itakura Y, Albouze G, et al:Factors influencing progression of renal failure in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 6:1634-1642, 1995.
PubMed
19) King BF, Torres VE, Brummer ME, et al:Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int 64:2214-2221, 2003.
PubMed
20) Chapman AB, Johnson AM, Gabow PA, et al:Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5:1349-1354, 1994.
PubMed
21) Woo D:Apoptosis and loss of renal tissue in polycystic kidney diseases. N Engl J Med 333:18-25, 1995.
PubMed
22) Martinez JR, Grantham JJ:Polycystic kidney disease:Etiology, pathogenesis, and treatment. Dis Mon 41:693-765, 1995.
PubMed
23) Klahr S, Levey AS, Beck GJ, et al:The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330:877-884, 1994.
PubMed
24) Hadimeri H, Johansson AC, Haraldsson B, et al:CAPD in patients with autosomal dominant polycystic kidney disease. Perit Dial Int 18:429-432, 1998.
PubMed
25) わが国の慢性透析療法の現況 (2003年12月31日現在) . (社) 日本透析医学会統計調査委員会, 2003.
 
26) Ritz E, Zeier M, Schneider P, et al:Cardiovascular mortality of patients with polycystic kidney disease on dialysis:is there a lesson to Iearn?Nephron 66:125-128, 1994.
 
27) Shiroyanagi Y, Tanabe K, Hashimoto Y, et al:Kidney transplantation in the recipient with autosomaldominant polycystic kidney disease:a single center experience. Transplantation Proceedings 32:1841-1843, 2000.
PubMed
28) Errasti P, Manrique J, Lavilla J, et al:Autosomal-dominant polycystic kidney disease:High prevalence of graft loss for death-related malignancies and cardiovascular risk factors, Transplantation Proceedings 35:1717-1719, 2003.
PubMed
29) Stiasny B, Ziebell D, Graf S, et al:Clinical aspects of renal transplantation in polycystic kidney disease. Clinical Nephrology 58 (1):16-24, 2002.
PubMed
30) Glassman DT, Nipkow L, Bartlett ST, et al:Bilateral nephrectomy with concomitant renal graft transplantation for autosomal dominant polycystic kidney disease. J Urology 164:661-664, 2000.
PubMed
31) Watoson ML:Hypertension in polycystic disease. In:Polycystic Kidney Disease. Watson ML, et al (eds) . p407-429, 0xford University Press, Oxford, 1996.
 
32) Higashihara E, Aso Y, Shimazaki J, et al:Clinical aspects of polycystic kidney disease. J Urol 147:329-332, 1992.
PubMed
33) Hansson L, Karlander LE, Lundgern W, et al:Hypertension in polycystic kidney disease. Scand J Uro Nephrol 8:203-205, 1974.
 
34) Gabow PA, Johnson AM, Kaehny WD, et al:Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 41:1311-1319, 1992.
PubMed
35) Al-Nimuri MA, Komers R, Oyama TT, et al:Endothelial-derived vasoactive mediators in polycystic kidney disease. Kidney Int 63:1776-1784, 2003.
 
36) Wang D, Iversen J, Wilcox CS, et al:Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 64:1381-1388, 2003.
PubMed
37) Kim K, Drummond I, Ibraghimov-Beskrovnaya O, et al:Polycystine 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci USA 97:1731-1736, 2000.
 
38) Fick GM, Johnson AM, Hammond WS, et al:Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5:2048-2056, 1995.
PubMed
39) Ecder T, Chapman AB, Brosnahan GM, et al:Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 35:427-432, 2000.
 
40) Ecder T, Edelstein CL, Chapman AB, et al:Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 14:1113-1116, 1999.
PubMed
41) van Dijk MA, Breuning MH, Duiser R, et al:No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 18:2314-2320, 2003.
PubMed
42) Nutahara K, Higashihara E, Horie S, et al:Calcium channel blocker versus angiotensin H recepter blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract 99:c18-c23, 2005.
 
43) Belz MM, Hughes RL, Kaehny WD, et al:Familial clustering of ruptured intracranial aneurysms in autosomal dominant polycystic kidney disease. Am J Kidney Dis 38:770-776, 2001.
PubMed
44) 東原英二:多発性嚢胞腎の治療. 臨床と研究76:1505-1511, 1999.
 
45) 東原英二:多発性嚢胞腎. 日本内科学会雑誌87:1298-1304, 1998.
 
46) Zeier M, Geberth S, Ritz E, et al:Adult dominant polycystic kidney disease-Clinical problems. Nephron 49:177-183, 1988.
PubMed
47) 円山英昭:目本病理剖検輯報による多嚢胞性疾患の統計的観察. 最新医学41:141-149, 1986.
 
48) Ryu SJ:Intracranial hemorrhage in patients with polycystic kidney disease. Stroke 21:291-294, 1990.
PubMed
49) Kushi H, Shibuya T, Tsubokawa T, et al:Intracranial hemorrhage associated with polycystic liver and kidney disease-two case reports. Nihon Univ J Med 34:161-167, 1992.
 
50) 石倉宏恭, 谷口. 智行, 田中孝也, ほか:多発性肝腎嚢胞症に合併した頭蓋内出血症例の検討. JJAAM 2:652-656, 1991.
 
51) 野口明男, 塩川芳昭, 齋藤勇:脳出血. 臨床と研究76:2357-2360, 1999.
 
52) 金谷春之, ほか:高血圧性脳出血における新しいNeumlogical GradingおよびCTによる血腫分類とその予後について. 高血圧性脳出血の外科皿. 第7回脳卒中の外科研究会. p265-270, 1978.
 
53) Schievink WI, Torres VE, Piepgras DG, et al:Saccular intracranial aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 3:88-95, 1992.
PubMed
54) Suter W:Das kongenitale aneurysma der basalen gehirnarterien und cystennieren. Schweiz Med Wochenschr 79:471. 476, 1949.
 
55) Brown RAP:Polycystic disease of the kidneys and intracranial aneurysms. The etiology and interrelationship of these conditions. Review of the recent literature and report of seven cases in which both conditions coexisted. Glasgow Med J 32:333-348, 1951.
PubMed
56) Bigelow NH:The association of polycystic kidneys with intracranial aneurysms and other related disorders. Am J Med Sci 225:485-494, 1953.
PubMed
57) Chapman AB, Rubinstein D, Hughes R, et al:Intracranial aneurysms in autosomal dominant polycystic kidney disease. N Engl J Med 327:916-920, 1992.
PubMed
58) Huston J, Torres VE, Sullivan PP, et al:Value of magnetic resonance angiography for the detection of intracranial aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 3:1871-1877, 1993.
 
59) Ruggieri PM, Poulos N, Masaryk TJ, et al:Occult intracranial aneurysms in polycystic kidney disease:screening with MR angiography. Radiology 191:33-39, 1994.
PubMed
60) Atkinson JLD, Sundt TM Jr, Houser OW, et al:Angiographic frequency of anterior circulation interacranial aneurysms. J Neurosurg 70:551-555, 1989.
 
61) Pirson Y, Chauveau D:Cerebral aneurysms, In Polycystic kidney disease. Watson M, Torres V (eds). p205-227, 0xford University press, Oxford, England, 1996.
 
62) McCormick WF, Nofzinger JD:Saccular intracranial aneurysms:an autopsy study. J Neurosurg 22:155-159, 1965.
PubMed
63) Inagawa T, Hirano A:Autopsy study of unruptured incidental intracranial aneurysms. Surg Neurol 34:361-365, 1990.
PubMed
64) Mariani L, Bianchetti MG, Schroth G, et al:Cerebral aneurysms in patients with autosomal dominant polycystic kidney disease-to screen, to clip, to coil? Nephrol Dial Transplant 14:2319-2322, 1999.
PubMed
65) Chauveau D, Pirson Y, Verellen-Dumoulin C, et al:Intracranial aneurysms in autosomal dominant polycystic kidney disease. Kidney Int 45:1140-1146, 1994.
PubMed
66) Lozano AM, Leblanc R:Cerebral aneurysms and polycystic kidney disease:A critical review. The Canadian. J Neurological Sciences 19:222-227, 1992.
 
67) Chauveau D, Pirson Y, Grunfeld JP:Intracranial aneurysms and autosomal-dominant polycystic kidney disease:Preliminary results of a cooperative study (Abstract). Kidney Int 39:1321, 1991.
 
68) Kassell NF, Torner JC, Haley EC, et al:The international cooperative study on the timing of aneurysm surgery. Part 1;Overall management results. J Neurosurg 73:18-36, 1990.
 
69) Locksley HB:Report on the cooperative study of intracranial aneurysms and subarachnoid hemorrhage. Section V, part I. Natural history of subarachnoid hemorrhage, intracranial aneurysms and arteriovenous malformations. Based on 6368 cases in the cooperative study. J Neurosurg 25:219-239, 1967.
 
70) Wang PS, Longstreth WT, Koepsell TD:Subarachnoid hemorrhage and family history:A population-based case control study. Arch Neurol 52:202-204, 1995.
PubMed
71) Bromberg JEC, Rinkel GJE, Algra A, et al:Subarachnoid in first and second degree relatives of patients with subarachnoid haemorrhage. BMJ 311:288-289, 1995.
 
72) Schievink WI, Schaid DJ, Michels VV, et al:Familial aneurismal subarachnoid hemorrhage:A community-based study. J Neurosurg 83:426-429, 1995.
 
73) Wiebers DO, Whisnant JP, Sundt TM, et al:The significance of unruptured intracranial saccular aneurysms. J Neurosurg 66:23-29, 1987.
PubMed
74) Wiebers DO, Whisnant JP, O'Fallon WM:The natural history of unruptured intracranial aneurysms. N Engl J Med 304:696-698, 1981.
PubMed
75) Lozano AM, Leblanc R:Cerebral aneurysms and polycystic kidney disease:A critical review. The Canadian J Neurological Sciences 19:222-227, 1992.
 
76) Levey AS:Cerebral aneurysms. In:Problems in diagnosis and management of polycystic kidney disease. Grantham JJ, Gardner KD (eds). p135-144, PKR Foundation, Kansas City, 1985.
 
77) Dalgaard OZ:Bilateral polycystic disease of the kidneys:A follow-up of two hundred and eighty-four patients and their families. Acta Med Scand 328:S1-S255, 1957. (suppl 1)
 
78) Iglesias CG, Torres VE, Offord KP, et al:Holley KE, Beard CM, Kuland LT:Epidemiology of adult polycystic kidney disease, Olmstead County, Minnesota. Am J Kidney Dis 2:630-639, 1983.
 
79) Watson ML:Complications of polycystic kidney disease. Kidney Int 51:353-365, 1997.
PubMed
80) Butler WE, Barker FG, Crowell RM:Patients with polycystic kidney disease would benefit from routine magnetic resonance angiographic screening for intracerebral aneurysms:A decision analysis. Neurosurgery 38:506-515, 1996.
PubMed
81) Lever AS, Pauker SG, Kassirer JP:Occult intracranial aneurysms in polycystic kidney disease:When is cerebral arteriography in dicated? N Engl Med 308:986-994, 1983.
 
82) Vega C, Kwoon J, Lavine S, et al:Intracranial aneurysms:Current evidence and clinical practice. Am Family Physician 66:601-608, 2002.
PubMed
83) Pirson Y, Chauveau D, Torres V:Management of cerebral aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 13:269-276, 2002.
PubMed
84) Slaba SG, El-Hajj LF, Abboud GA, et al:Selective angiography of cerebralaneurysm using gadodiamide in polycystic kidney disease with renal insufficiency. AJR 175:1467-1468, 2000.
 
85) Nakajima F, Shibahara N, Arai M, et al:Ruptured cerebral aneurysm not detected by magnetic resonance angiography in juvenile autosomal dominant polycystic kidney. Int J Urol 7:153-156, 2000.
 
86) Nakajima F, Shibuhara N, Arai M, et al:Intracranial aneurysms and autosomal dominant polycystic kidney disease:Followup study by magnetic resonance angiography. J Urology 164:311-313, 2000.
 
87) Stamm ER, Townsend RR, Johnson AM, et al:Frequency of ovarian cysts in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 34:120-124, 1999.
PubMed
88) Belet U, Danaci M, Sarikaya S, et al:Prevalence of epididymal, seminal vesicle, prostate, and testicular cysts in autosomal dominant polycystic kidney disease. Urology 60:138-141, 2002.
PubMed
89) Danaci M, Akpolat T, Bastemir M, et al:The prevalence of seminal vesicle cysts in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 13:2825-2828, 1998.
PubMed
90) Rizk D, Chapman AB:Cystic and inherited kidney diseases. Am J Kidney Dis 42:1305-1317, 2003.
PubMed
91) Gibson P, Watson ML:Cyst infection in polycystic kidney disease:a clinical challenge. Nephrol Dial Transplant 13:2455-2457, 1998.
PubMed
92) Chicoskie C, Chaoui A, Kuligowska E, et al:MRI isolation of infected renal cyst in autosomal dominant polycystic kidney disease. Clin Imaging 25:114-117, 2001.
PubMed
93) Bleeker-Rovers CP, de Sevaux RG, van Hmersvelt HW, et al:Diagnosis of renal and hepatic cyst infections by 18-F-fluorodeoxyglucose positron emission tomography in autosomal dominant polycystic kidney disease. Am J Kidney Dis 41:E18-21, 2003.
 
94) Elzinga LW, Golper TA, Rashad AL, et al:Trimethoprim-sulfamethoxazole in cyst fluid from autosomal dominant polycystic kidneys. Kidney Int 32:884-888, 1987.
PubMed
95) Ubara Y, Tagami T, Sawa N, et al:Renal contraction therapy for enlarged polycystic kidneys by transcatheter arterial embolization in hemodialysis patients. Am J Kidney Dis 39:571-579, 2002.
PubMed
96) 乳原善文, 田上哲夫, 星野純一, ほか:多発性嚢胞腎の血管内治療. 日本臨床62 (6):578-584, 2004.
 
97) Luke PP, Spodek J:Hand-assisted laparoscopic resection of the massive autosomal dominant polycystic kidney. Urology 63:369-372, 2004.
PubMed
98) Ubara Y, Takei R, Hoshino J, et al:Intravascular embolization therapy in a patient with an enlarged polycystic liver. Am J Kidney Dis 43:733-738, 2004.
 
99) Hossack KF, Leddy CL, Johnson AM, et al:Echocardiographic findings in autosomal dominant polycystic kidney disease. N Engl J Med 319:907-912, 1988.
PubMed
100) Perrone RD:Extrarenal manifestations of ADPKD. Kidney Int 51:2022-2036, 1997.
PubMed
101) Schrier R, McFann K, Johnson A, et al:Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease:results of a seven-year prospective randomized study. J Am Soc Nephrol 13:1733-1739, 2002.
PubMed
102) Lumiaho A, Ikaheimo R, Miettinen R, et al:Mitral valve prolapse and mitral regurgitation are common in patients with polycystic kidney disease type 1. Am J Kidney Dis 38:1208-1216, 2001.
PubMed
103) Delakas D, Daskalopoulos G, Cranidis A:Extracorporeal shockwave lithotripsy for urinary calculi in autosomal dominant polycystic kidney disease. J Endourol 11:167-170, 1997.
PubMed
104) Gabow PA, Duley I, Johnson AM:Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease. AJKD 20:140-143, 1992.
PubMed
105) Glassberg KI:Renal Dysgenesis and cystic disease of the kidney. In Campbells Urology 8th edn, Walsh, Retik, Vaughan, Wein (eds) . p1925, Elsevier Science, Philadelphia, 2002.
 
106) Lederman ED, McCoy G, Conti DJ, et al:Diverticulitis and polycystic kidney disease. Am Surg 66:200-203, 2000.
PubMed
107) Sharp CK, Zeligman BE, Johnson AM, et al:Evaluation of colonic diverticular disease in autosomal dominant polycystic kidney disease without end-stage renal disease. Am J Kidney Dis 34:863-868, 1999.
PubMed
108) Chapman AB, Johnson AM, Gabow PA:Pregnancy Outcome and Its Relationship to Progression of Renal Failure in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 5:1178-1185, 1994.
PubMed
109) Okada H, Fujioka H, Tatsumi N, et al:Assisted reproduction for infertile patients with 9+0 immotile spermatozoa associated with autosomal dominant polycystic kidney disease. Hum Reprod 14:110-113, 1999. Erratum in:Hum Reprod 14:1166, 1999.
 
110) Gabow PA:Autosomal Dominant Polycystic Kidney Disease. N Engl J Med 329:332-342, 1993.
PubMed
111) Geberth S, Stier E, Zeier M, et al:More Adverse Renal Prognosis of Autosomal Dominant Polycystic Kidney Disease in families with Primary hypertension. J Am Soc Nephrol 6:1643-1648, 1995.
PubMed
112) Chapman AB:Cystic Disease in Women:Clinical Characteristics and Medical Management. Adv Renal Replace Ther 10:24-30, 2003.
PubMed
113) Hammond L, Mckenna PH:Spontaneous Neonatal Pegression of Prenataly Detected Renal Cysts in Autosomal Dominant Polycystic Kidney Disease. J Urology 171:331-332, 2004.
 
114) Brun M, Maugey-Laulom B, Erin D, et al:Prenatal Sonographic Patterns in Autosomal Dominant Polycystic Kidney Disease:A Multicenter study. Urtrasound Obstet Gynecol 24:55-61, 2004.
 
115) Roume J, Ville Y:Prenatal Diagnosis of Genetic Renal Diseases:Breaking the Code. Urtrasound Obstet Gynecol 24:10-18, 2004.
PubMed
116) Wilson PD, Guay-Woodford L:Pathophysiology and Clinical Management of Polycystic Kidney Disease in Women. Semin Nephrol 19:123. 132, 1999.
 
117) Lu J, Bankovic-Calic N, Ogborn M, et al:Detrimental effects of a high fat diet in early renal injury are ameriolated by fish oil in Han:SPRD-cy rats. J Nut 133:180-186, 2003.
 
P.318 掲載の参考文献
1) Higashihara E, Aso Y, Shimazaki J, et al:Clinical aspects of polycystic kidney disease. J Urol 147:329-332, 1992.
PubMed
2) 東原英二, 伊藤晴夫, 島崎淳, ほか:膀胱尿管逆流と腎瘢痕. 日泌尿会誌82:1781-1789, 1991.
 
3) Higashihara E, Nutahara K, Kojima M, et al:Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. Nephron 80:421-427, 1998.
PubMed
4) Higashihara E, Horie S:Genetic study of ADPKD in Japan. Kidney Int 47:729, 1995.
 
5) Horie S, Higashihara E, Nutahara K, et al:Mediation of renal cyst formation by hepatocyte growth factor. Lancet 344:789-791, 1994.
PubMed
6) Mizoguchi M, Tamura T, Yamaki A, et al:Mutations of the PKDI gene among Japanese autosomal dominant polycystic kidney disease patients, including, one heterozygous mutation identified in members of the same family. J Hum Genet 46:511-517, 2001.
 
7) Mizoguchi M, Tmamura T, Yamaki A, et al:Genotypes of autosomal dominant polycystic kidney disease in Japanese. J Hum Genet 47:51-54, 2002.
 
8) Mcpherson EA, Luo Z, Brown RA, et al:Chymase-like Angiotensin II-Generating activity in end-stage human autosomal dominant polyclstic kidney disease. J Am Nephrol 15:493-500, 2004.
PubMed
9) Muto S, Aiba A, Saito Y, et al:Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 11:1731-1742, 2002
PubMed
10) Nutahara K, Higashihara E, Horie S, et al:Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract 99:c18-c23, 2005.
PubMed
11) Ubara Y, Katori H, Tagami T, et al:Transcatheter renal arterial embolization therapy on a patient with polycystic kidney disease. Am J Kidney Dis 34:926-931, 1999.
PubMed
12) 香村衡一, ほか:常染色体優性多発性嚢胞腎による腹部腫大に対する腎動脈塞栓術. 日本透析医学会和文誌 (印刷中), 2006.
 
P.333 掲載の参考文献
1) Gattone VH 2nd, Maser RL, Tian C, et al:Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet 24:309-318, 1999.
PubMed
2) Gattone VH 2nd, Wang X, Harris PC, et al:Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9:1323-1326, 2003.
PubMed
3) Torres VE, Wang X, Qian Q, et al:Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10:363-364, 2004.
 
4) Wang X, Gattone V 2nd, Harris PC, et al:Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-410610 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16:846-851, 2005.
 
5) Yamamura Y, Ogawa H, Chihara T, et al:OPC-21268, an orally effective, nonpeptide vasopressin VI receptor antagonist. Science 252:572-574, 1991.
 
6) Yamamura Y, Ogawa H, Yamashita H, et al:Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 105:787-791, 1992.
PubMed
7) Noda Y, Sasaki S:Molecular mechanisms and drug development in aquaporin water channel diseases:molecular mechanism of water channel aquaporin-2 trafficking. J Pharmacol Sci 96:249-254, 2004.
PubMed
8) Yamamura Y, Nakamura S, Itoh S, et al:OPC-41061, a highly potent human vasopressin V2-receptor antagonist:pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287:860-867, 1998.
PubMed
9) Hirano T, Yamamura Y, Nakamura S, et al:Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 292:288-294, 2000.
PubMed
10) Hanaoka K, Guggino WB:cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 11:1179-1187, 2000.
 
11) Yamaguchi T, Pelling JC, Ramaswamy NT, et al:cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 57:1460-1471, 2000.
PubMed
12) Hanaoka K, Qian F, Boletta A, et al:Co-assembly of polycystin-1 and-2 produces unique cation-permeable currents. Nature 408:990-994, 2000.
PubMed
13) Yamaguchi T, Wallace DP, Magenheimer BS, et al:Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 279:40419-40430, 2004.
 
14) Nagao S, Yamaguchi T, Kusaka M, et al:Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease. Kidney Int 63:427-37, 2003.
PubMed
15) Yamaguchi T, Nagao S, Wallace DP, et al:Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 63:1983-1994, 2003.
PubMed
16) Li X, Luo Y, Starremans PG, et al:Polycystin-1 and polycystin-2 regulate the cell cycle through the helix-loop-helix inhibitor Id2. Nature Cell Biol 7:1102-1112, 2005.
 
17) Michalski A, Grzeszczak W:The influence of hypervolemia on electrolytes level and hormones regulating volemia in patients with autosomal dominant polycystic kidney disease (ADPKD). Pol Arch Med Wewn 96:329-43, 1996.
 
18) Nutahara K, Higashihara E, Horie S, et al:Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract 99:c18-23, 2005.
PubMed
19) Gheorghiade M, Niazi I, Ouyang J, et al:Tolvaptan Investigators. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure:results from a double-blind, randomized trial. Circulation 107:2690-2696, 2003.
PubMed
20) Gheorghiade M, Gattis WA, O'Connor CM, et al:Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure:a randomized controlled trial. JAMA 291:1963-1971, 2004.
PubMed

書評

最近チェックした商品履歴

Loading...